Kaplan and Sadocks Comprehensive Textbook of Psychiatry
Livrare gratis la comenzi peste 500 RON. Pentru celelalte comenzi livrarea este 20 RON.
Disponibilitate: La comanda in aproximativ 4 saptamani
Editura: LWW
Limba: Engleza
Nr. pagini: 5500
Coperta: Hardcover
Dimensiuni: 213 x 276 mm
An aparitie: 8 mai 2024
The gold standard reference for all those who work with people with mental illness, Kaplan & Sadock's Comprehensive Textbook of Psychiatry, edited by Drs. Robert Boland and Marcia L. Verduin, has consistently kept pace with the rapid growth of research and knowledge in neural science, as well as biological and psychological science. This two-volume eleventh edition offers the expertise of more than 600 renowned contributors who cover the full range of psychiatry and mental health, including neural science, genetics, neuropsychiatry, psychopharmacology, and other key areas.
VOLUME I
1 Neural Sciences
1.1 The Neuroscience of Psychiatry
REVIEW OF THE NEUROSCIENCE CHAPTERS
CONCLUSIONS
1.2 Functional Neuroanatomy
PRINCIPLES OF BRAIN ORGANIZATION
STRUCTURAL COMPONENTS
FUNCTIONAL BRAIN SYSTEMS
IMPLICATIONS FOR BIOLOGICALLY BASED DIAGNOSTIC SYSTEMS
1.3 Functional Genomics of Human Brain Development
THE TRANSCRIPTIONAL LANDSCAPE OF THE DEVELOPING HUMAN CNS
THE REGULATORY LANDSCAPE OF THE DEVELOPING HUMAN CNS
EPIGENETIC REGULATION OF HUMAN BRAIN DEVELOPMENT
TRANSCRIPTIONAL AND EPIGENETIC DYSREGULATION IN NEURODEVELOPMENTAL AND PSYCHIATRIC DISORDERS
FUTURE DIRECTIONS
1.4 Neural Development and Neurogenesis
NEURAL DEVELOPMENT AND NEUROGENESIS
OVERVIEW OF NERVOUS SYSTEM MORPHOLOGIC DEVELOPMENT
THE CONCEPT OF NEURAL PATTERNING
REGULATION OF NEURODEVELOPMENT BY EXTRACELLULAR FACTORS
POSTNATAL NEUROGENESIS IN MAMMALS: SUBVENTRICULAR ZONE AND HIPPOCAMPAL DENTATE GYRUS
1.5 Cellular and Synaptic Basis of Neural Signaling
PRINCIPLES OF CELLULAR ELECTROPHYSIOLOGY
ION CHANNELS
NEUROTRANSMITTERS AND ION CHANNELS
CLINICAL ASPECTS OF ION CHANNELS
SUMMARY
ACKNOWLEDGMENTS
1.6 Amino Acid Neurotransmitters
GLUTAMIC ACID
CONCLUSION
1.7 Biogenic Amine Neurotransmitters
DOPAMINE AND NOREPINEPHRINE
SEROTONIN
ACETYLCHOLINE
HISTAMINE
TRACE AMINES
1.8 Neuropeptides: Biology, Regulation and Role in Neuropsychiatric Disorders
INVESTIGATING NEUROPEPTIDE FUNCTION
BIOSYNTHESIS
DISTRIBUTION AND REGULATION
NEUROPEPTIDE SIGNALING
NEUROPEPTIDE SYSTEMS AS DRUG TARGETS
SPECIFIC NEUROPEPTIDES AS EXEMPLARS OF NEUROPEPTIDE BIOLOGY
FUTURE DIRECTIONS
1.9 Novel Neurotransmitters
GASES AS NEUROTRANSMITTERS
ENDOCANNABINOIDS: FROM MARIJUANA TO NEUROTRANSMISSION
EICOSANOIDS
NEUROSTEROIDS
NOVEL NEUROTRANSMITTERS: BEYOND THE CLASSICAL DEFINITION OF NEUROTRANSMITTER
1.10 Neurotrophic Factors
THE NEUROTROPHIN FAMILY
NEUROTROPHIN RECEPTORS
NEUROTROPHIC FACTORS AND DEVELOPMENT
NEUROTROPHINS AND SYNAPTIC PLASTICITY
NEUROTROPHINS AND METABOLISM
CORRELATES TO NEURODEGENERATIVE DISORDERS
CORRELATES TO PSYCHIATRIC DISORDERS
NEUROTROPHIC HYPOTHESIS FOR MOOD DISORDERS: THERAPEUTIC POTENTIAL OF NEUROTROPHINS
ACKNOWLEDGMENTS
1.11 Intraneuronal Signaling
OVERVIEW OF NEURONAL SIGNAL TRANSDUCTION
G-PROTEIN–COUPLED RECEPTOR SIGNALING
TYROSINE KINASE PATHWAYS
WNT SIGNALING
SYNAPTIC PLASTICITY
SIGNALING COMPLEXES AND SCAFFOLDS
REMOTE CONTROL OF INTRANEURONAL SIGNALING
FUTURE DIRECTIONS
1.12 Psychoneuroendocrinology
HORMONE EVOLUTION
HORMONE CLASSIFICATION
HORMONE SECRETION
HORMONE SYNTHESIS AND STRUCTURE
CELLULAR MODE OF ACTION
CHARACTERISTICS OF ENDOCRINE ACTIVITY
PHARMACOGENETICS AND PHARMACOGENOMICS
DEVELOPMENTAL PSYCHONEUROENDOCRINOLOGY AND EPIGENETIC TRANSMISSION
PSYCHONEUROENDOCRINOLOGY METHODOLOGY IN HUMANS
HYPOTHALAMIC–PITUITARY–ADRENAL AXIS
METABOLIC SYNDROME
PROOPIOMELANOCORTIN, MELANOCORTINS, MELANOCYTE-STIMULATING HORMONE, AND MELATONIN
ENDOGENOUS OPIOIDS
HYPOTHALAMIC–PITUITARY–GONADAL AXIS
PREGNENOLONE AND ALLOPREGNANOLONE
PROLACTIN
HYPOTHALAMIC–PITUITARY–THYROID AXIS
PARATHYROID HORMONE
GROWTH HORMONE
SOMATOSTATIN
ARGININE VASOPRESSIN
OXYTOCIN
NEUROPEPTIDE Y
GALANIN
INSULIN
LEPTIN/GHRELIN/GLUCAGON-LIKE PEPTIDE
CHOLECYSTOKININ
GASTRIN AND GASTRIN-RELEASING PEPTIDE
NEUROTENSIN
FUTURE DIRECTIONS: ENDOCRINE VARIABLES IN THE DIAGNOSIS AND TREATMENT OF PSYCHIATRIC DISORDERS
1.13 Immune–Brain Interactions in Psychiatry
COMPONENTS OF THE IMMUNE SYSTEM
IMMUNE–BRAIN COMMUNICATION
SOCIAL ADVERSITY, ENVIRONMENTAL THREATS, AND THE IMMUNE SYSTEM
RELEVANCE OF IMMUNE–CNS INTERACTIONS TO PATHOLOGY AND TREATMENTS IN PSYCHIATRY
FACTORS ASSOCIATED WITH IMMUNE ACTIVATION IN PSYCHIATRY
CONCLUSIONS TO THE CHAPTER
1.14 Chronobiology, Circadian Rhythm, and Psychiatry
CIRCADIAN PACEMAKERS
SLEEP AND CIRCADIAN RHYTHMS
SEASONALITY
CIRCADIAN RHYTHMS IN PSYCHIATRIC DISORDERS
NONSEASONAL UNIPOLAR DEPRESSION AND CIRCADIAN RHYTHMS
CIRCADIAN RHYTHMS AND PHARMACOTHERAPY
FUTURE CONSIDERATIONS
1.15 Basic Science of Sleep
NORMAL HUMAN SLEEP
EFFECTS OF AGE ON SLEEP
MONITORING HUMAN SLEEP
PHYSIOLOGY IN SLEEP
NEUROBIOLOGY OF SLEEP AND WAKEFULNESS
CIRCADIAN AND HOMEOSTATIC REGULATION OF SLEEP
HOMEOSTATIC REGULATION OF SLEEP AND THE EFFECTS OF SLEEP DEPRIVATION
DREAMING
THE FUNCTIONS OF SLEEP
SLEEP AND PSYCHIATRY
1.16 Pain Systems: Interface with Affective and Motivational Mechanisms
PAIN SYSTEMS
PAIN AND MOTIVATIONAL MECHANISMS
PAIN AND AFFECTIVE REGULATION AND DYSREGULATION
COGNITIVE PROCESSING AND PAIN
FUTURE DIRECTIONS
1.17 Basic Science of Appetite
SIGNALS FOR MEAL INITIATION
MEAL MAINTENANCE
SATIATION AND POSTPRANDIAL SATIETY
BRAIN MECHANISMS OF APPETITE
PHYSIOLOGIC MODULATORS OF APPETITE
PSYCHIATRIC EATING DISORDERS
SUMMARY
1.18 Genome, Transcriptome, and Proteome: The Molecular Genetics, Biochemistry, and Multi-Omics Underlying the Neurobiology of Mental Disorders
THE ORGANIZATION AND STRUCTURE OF THE HUMAN GENOME
HUMAN GENETIC VARIATION
THE FUNCTION OF THE GENOME
REGULATION OF TRANSCRIPTION AND THE TRANSCRIPTOME
PROTEIN REGULATION AND THE PROTEOME
PHARMACOGENOMICS IN NEUROPSYCHIATRIC DISORDERS
THE BRAIN AS A SYSTEM
FUTURE PROSPECTS
1.19 Gene Mapping Investigations of Psychiatric Disorders
EPIDEMIOLOGY
BASIC CONCEPTS OF GENE MAPPING
MAPPING STRATEGIES
THE PHENOTYPE
PROGRESS IN THE GENETIC DISSECTION OF SPECIFIC DISORDERS
ALZHEIMER DISEASE
AUTISM
BIPOLAR DISORDER, SCHIZOPHRENIA, MAJOR DEPRESSION, AND ANXIETY
GENETIC OVERLAP AMONG PSYCHIATRIC DISORDERS
FUTURE DIRECTIONS
1.20 Epigenetics in Psychiatry: The Promise for New Biomarkers and Treatments
THE EPIGENETICS MACHINERY
EPIGENETICS IN PRECLINICAL WORK
EPIGENETIC MECHANISMS IN PSYCHIATRIC ILLNESS
1.21 Pharmacogenetics
THE SEARCH FOR INDIVIDUALIZED PSYCHOPHARMACOLOGY
PHARMACOGENETICS AND PHARMACOGENOMICS
PHARMACOKINETICS AND PHARMACODYNAMICS
PHARMACOGENETICS OF PHARMACOKINETICS
PHARMACOKINETICS BEYOND DRUG LEVELS OF THE PARENT DRUG
THE PHARMACOKINETICS OF ONE DRUG MAY GENERATE MULTIPLE ACTIVE COMPOUNDS
PHARMACOKINETICS AND ALCOHOLISM
PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG ENTRY INTO THE BRAIN
GEOGRAPHIC AND ETHNIC PHARMACOKINETIC VARIABILITY
CULTURE OR ETHNICITY-RELATED PHARMACOGENETICS?
PHARMACOGENETICS OF PHARMACODYNAMICS
PHARMACOGENETICS OF SPECIFIC PSYCHIATRIC DISORDERS
PHARMACOGENETIC TESTING: A BRIEF OVERVIEW
CONCLUSIONS
1.22 Animal Models in Psychiatry
THE USE OF ANIMAL MODELS IN PSYCHIATRIC RESEARCH
NEGATIVE VALENCE
POSITIVE VALENCE
COGNITION
SOCIAL FUNCTIONING
SLEEP AND AROUSAL
CONCLUDING REMARKS AND FUTURE DIRECTIONS
1.23 Basic Systems Neuroscience
THE IMPORTANCE AND UTILITY OF ANIMAL MODELS
NEURAL ELECTRICAL ACTIVITY AND NEURAL CODES
SUMMARY
1.24 Computational Modeling Approaches to Psychiatry
BIOPHYSICALLY BASED CIRCUIT MODELS
COGNITIVE PSYCHIATRIC NEUROSCIENCE AND CONNECTIONIST MODELS
MATHEMATICAL MODELS OF BEHAVIOR
MODELING NEUROPHYSIOLOGIC BIOMARKERS
FUTURE CHALLENGES
1.25 Nuclear Magnetic Resonance Imaging and Spectroscopy: Basic Principles and Recent Findings in Neuropsychiatric Disorders
HISTORY
BASIC PHYSICS OF NMR, MRS, AND MRI
SYSTEM HARDWARE
FOURIER TRANSFORM
MRI METHODOLOGY
APPLICATIONS OF STRUCTURAL IMAGING TO PSYCHIATRY
FUNCTIONAL MRI METHODOLOGY
APPLICATIONS OF FMRI IN PSYCHIATRY
1H MRS
31P MRS
13C MRS
APPLICATIONS OF MRS IN PSYCHIATRY
DEUTERIUM METABOLIC IMAGING (DMI)
PRACTICAL CONSIDERATIONS
FUTURE DIRECTIONS
1.26 Electroencephalography in Psychiatry
HISTORY
BASIC PRINCIPLES OF ELECTROENCEPHALOGRAPHY
EEG RECORDING AND RELATED METHODOLOGY
EEG CHARACTERISTIC FEATURES
EEG IN APPLIED CLINICAL PRACTICE
EEG IN PSYCHIATRY
EEG ALTERATIONS FROM MEDICATIONS AND DRUGS
EEG AND EXPERIMENTAL RESEARCH PARADIGMS
SUMMARY AND FUTURE DIRECTIONS: EEG IN THE SYSTEMATIC STUDY OF PSYCHOPATHOLOGY
TRANSLATION OF RESEARCH FINDINGS TO CLINICAL APPLICATIONS
1.27 Radiotracer Imaging with Positron Emission Tomography and Single Photon Emission Computed Tomography: Fundamental Principles, Methodology and Role in Neuropsychiatric Research
OVERVIEW
BASIC PHYSICAL PRINCIPLES
PHARMACOKINETIC MODELS AND METHODS, EXPERIMENTAL DESIGNS
RADIOTRACERS
NEUROCHEMICAL IMAGING IN PSYCHIATRIC RESEARCH
NEUROINFLAMMATION IMAGING IN PSYCHIATRY
FUTURE DIRECTIONS
1.28 Functional Brain Connectivity and Psychopathology
THE ADVENT OF STUDYING FUNCTIONAL CONNECTIVITY
RESTING-STATE FUNCTIONAL CONNECTIVITY
RESTING-STATE FUNCTIONAL CONNECTIVITY NETWORKS
MODALITIES FOR ASSESSING RESTING-STATE FUNCTIONAL CONNECTIVITY
METHODS FOR ANALYZING RESTING-STATE FUNCTIONAL CONNECTIVITY
BENEFITS AND CHALLENGES IN APPLYING RESTING-STATE FUNCTIONAL CONNECTIVITY ANALYSES TO THE STUDY OF PSYCHOPATHOLOGY
CONCLUSION
1.29 Neuropsychiatry of Self
INTRODUCTION
HISTORICAL CONSIDERATIONS
MULTIDIMENSIONALITY OF SELF-REPRESENTATION
CLINICAL PERSPECTIVE
FUTURE DIRECTIONS
1.30 Learning Theory and Psychosis, Anxiety, and Addiction
A BRIEF HISTORY OF LEARNING THEORIES
ADDICTION
ANXIETY
SYNTHESIS AND FUTURE DIRECTIONS
1.31 Neuroscience of Substance Use Disorders
PHASES OF THE ADDICTION PROCESS
THEORIES OF ADDICTION
BRAIN PATHWAYS IN ADDICTION
CELLULAR AND MOLECULAR SUBSTRATES OF ADDICTION
SEX DIFFERENCES IN SUBSTANCE USE DISORDERS
CURRENT TREATMENTS
2 Neuropsychiatry and Behavioral Neurology
2.1 The Neuropsychiatric Approach to the Patient
NEUROPSYCHIATRIC NEUROANATOMY
MODULARITY AND NEUROPSYCHIATRY
CLINICAL EVALUATION
THE NEUROPSYCHIATRIC PHYSICAL EXAMINATION
FOCAL NEUROBEHAVIORAL SYNDROMES
COMMON NEUROPSYCHIATRIC CONDITIONS
THE NEUROPSYCHIATRIC PERSPECTIVE
2.2 Neuropsychiatric Aspects of Cerebrovascular Disorders
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
COURSE AND PROGNOSIS
TREATMENT
ACKNOWLEDGMENTS
2.3 The Neuropsychiatry of Brain Tumors
PSYCHIATRIC CLASSIFICATION
BRAIN TUMORS
BRAIN TUMORS IN PSYCHIATRIC PATIENTS
PSYCHIATRIC SYMPTOMS IN BRAIN TUMOR PATIENTS
FUTURE DIRECTIONS
ACKNOWLEDGEMENTS
2.4 Neuropsychiatric Aspects of Epilepsy and Psychogenic Nonepileptic Seizures
NEUROPSYCHIATRIC ASPECTS OF EPILEPSY
PSYCHOGENIC NONEPILEPTIC SEIZURES
2.5 Neuropsychiatric Consequences of Traumatic Brain Injury
EPIDEMIOLOGY OF TBI
MECHANISMS OF TBI
NEUROIMAGING AND LABORATORY INVESTIGATIONS
CATEGORIZATION OF TRAUMATIC BRAIN INJURY SEVERITY
COGNITIVE MANIFESTATIONS AND SEQUELAE OF TBI
TREATMENT OF COGNITIVE IMPAIRMENTS
TBI AND LATER-LIFE NEURODEGENERATIVE DEMENTIA
NEUROPSYCHIATRIC DISTURBANCES FOLLOWING TRAUMATIC BRAIN INJURY
GENERAL MANAGEMENT PRINCIPLES
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
2.6 Neuropsychiatric Aspects of Movement Disorders
PARKINSON DISEASE
PRIMARY DEMENTIA SYNDROMES WITH PARKINSONIAN SIGNS
CEREBELLAR DISORDERS
2.7 Neuropsychiatric Aspects of Multiple Sclerosis and Other Demyelinating Disorders
MULTIPLE SCLEROSIS
CONCLUSION AND FUTURE DIRECTIONS
ACKNOWLEDGMENT
2.8 Neuropsychiatric Aspects of HIV Infection and AIDS
OVERVIEW OF HIV INFECTION AND AIDS
PSYCHIATRIC CONDITIONS IN THE HIV CARE
HIV-ASSOCIATED DEMENTIA
MAJOR DEPRESSION IN PATIENTS WITH HIV DISEASE
BIPOLAR (MANIC-DEPRESSIVE) ILLNESSES IN PATIENTS WITH HIV DISEASE
SCHIZOPHRENIA IN PATIENTS WITH HIV DISEASE
ISSUES OF SUBSTANCE USE DISORDERS AND ADDICTION IN HIV DISEASE
ISSUES OF PERSONALITY IN PATIENTS INFECTED WITH HIV
PSYCHOLOGICAL PROBLEMS IN PATIENTS INFECTED WITH HIV
NEUROLOGIC COMPLICATIONS OF HIV AND AIDS
CONCLUSIONS
ACKNOWLEDGMENTS
2.9 Neuropsychiatric Aspects of Other Infectious Diseases (Non-HIV)
VIRUSES
BACTERIA
PROTOZOA
HELMINTHS
2.10 Neuropsychiatric Aspects of Prion Disease
NONFAMILIAL PRION DISEASES
FAMILIAL GENETIC PRION DISEASES
HISTORY OF PRION DISEASES
EPIDEMIOLOGY OF PRION DISEASES
PRION MOLECULAR BIOLOGY AND PATHOGENESIS
DIAGNOSIS AND CLINICAL FEATURES
NEUROPSYCHIATRIC WORKUP: THE STRUCTURED PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL HISTORY
COURSE AND PROGNOSIS
TREATMENT
PREVENTIVE MEASURES
2.11 Neuropsychiatric Aspects of Headache
DEFINITIONS
EPIDEMIOLOGY AND COURSE
ETIOLOGY
DIFFERENTIAL DIAGNOSIS AND CLINICAL EVALUATION
TREATMENT OF HEADACHE SYNDROMES
2.12 Neuropsychiatric Aspects of Neuromuscular Diseases
STRUCTURE OF THE PERIPHERAL NERVOUS SYSTEM
NEURONOPATHIES AND DISORDERS OF THE DORSAL ROOT GANGLION
PERIPHERAL NEUROPATHIES
NEUROMUSCULAR JUNCTION DISORDERS
MUSCLE DISEASES
MISCELLANEOUS NEUROMUSCULAR DISORDERS
FUTURE DIRECTIONS
2.13 Psychiatric Aspects of Child Neurology
FETAL ALCOHOL SPECTRUM DISORDERS
PREMATURE BIRTH AND LOW BIRTH WEIGHT
HUMAN IMMUNODEFICIENCY VIRUS IN CHILDREN AND ADOLESCENTS
EPILEPSY
TRAUMATIC BRAIN INJURY
OVERALL SUMMARY
ACKNOWLEDGMENT
2.14 Neuropsychiatry of Neurometabolic and Neuroendocrine Disorders
NEUROMETABOLIC SYNDROMES
NEUROENDOCRINE DISORDERS
FUTURE DIRECTIONS
2.15 Catatonia
BRIEF HISTORY AND NOSOLOGY
EPIDEMIOLOGY AND ETIOLOGY
DIAGNOSIS AND FEATURES
NEUROPATHOPHYSIOLOGY
MANAGEMENT AND TREATMENT
SUMMARY AND FUTURE DIRECTIONS
3 Contributions of the Psychological Sciences
3.1 Contributions of the Psychological Sciences: Sensation, Perception, and Cognition
COGNITIVE SCIENCE
NEURAL NETWORK GROWTH AND INTEGRATION
MIND AND BRAIN
ENERGY AND INFORMATION
INFORMATION PROCESSING
ATTENTION
SENSATION AND PERCEPTION
MEMORY SYSTEMS
CONSCIOUSNESS
SENSATION, PERCEPTION, AND COGNITION IN PSYCHIATRIC DISORDERS
FUTURE DIRECTIONS
3.2 Piaget and Cognitive Development: History, Theory, Extensions, and Modifications
PIAGET’S CLINICAL METHOD
GENETIC EPISTEMOLOGY
PIAGET THEORY
INTELLIGENCE: PIAGETIAN MODEL AND ITS ALTERNATIVES
NEW CONCEPTS OF INTELLIGENCE: EMOTIONAL BASIS OF INTELLIGENCE
TOWARD A GENERAL DEVELOPMENTAL MODEL
ACKNOWLEDGMENTS
3.3 Learning Theory
HISTORICAL CONTEXT
BASIC CONCEPTS AND CONSIDERATIONS
PAVLOVIAN CONDITIONING
OPERANT/INSTRUMENTAL LEARNING
PAVLOVIAN AND OPERANT LEARNING TOGETHER
ACKNOWLEDGMENT
3.4 Biology of Memory
MULTIPLE TYPES OF MEMORY
CORTICAL ORGANIZATION OF MEMORY
MEMORY SYSTEMS
FROM SYNAPSES TO MEMORY
MEMORY IMPAIRMENTS IN PSYCHIATRIC ILLNESS
ASSESSMENT OF MEMORY FUNCTIONS
IMPLICATIONS
ACKNOWLEDGMENT
3.5 Normality and Mental Health
MODEL A: MENTAL HEALTH AS ABOVE NORMAL
MODEL B: MENTAL HEALTH AS POSITIVE PSYCHOLOGY
MODEL C: MENTAL HEALTH AS MATURITY
MODEL D: MENTAL HEALTH AS RESILIENCE
MODEL E: MENTAL HEALTH AS SOCIOEMOTIONAL INTELLIGENCE
MODEL F: MENTAL HEALTH AS SUBJECTIVE WELL-BEING
MODEL G: MENTAL HEALTH AS POSITIVE OR “SPIRITUAL” EMOTIONS
FUTURE DIRECTIONS
3.6 Neuroscience of Psychoanalytic Object Relations Theory
BASICS OF BRAIN AND MIND SELF-ORGANIZATION
BASICS OF OBJECT RELATIONS THEORY
THE PRENATAL SOMATOSENSORY ORIGINS OF THE MIND
PHANTASY: THE BRAIN’S PHYLOGENETIC CODE FOR PRIMITIVE MENTAL FORMS
RECURSIVE CYCLES OF PROJECTION AND INTROJECTION ORGANIZE THE INNER AND THE OUTER WORLD
PARTIAL OBJECT RELATIONS
INTEGRATED OBJECT RELATIONS: COGNITIVE RECONCILIATION OF AFFECTIVE DICHOTOMIES
COGNITIVE AND NETWORK NEUROSCIENCE OF THE EXPERIENCE OF SELF
WORKING THROUGH AND BEYOND
Summary
ACKNOWLEDGMENT
4 Contribution of the Social Sciences
4.1 Neurocentrism: Implications for Addiction and the Courtroom
BRAIN AND MIND—WHY THEY ARE DIFFERENT
LEVELS OF ANALYSIS, ADDICTION, AND THE BRAIN DISEASE FALLACY
NEURAL CORRELATES AND VOLUNTARINESS COEXIST
NEUROCENTRISM, FREE WILL, AND LEGAL RESPONSIBILITY
CONCLUSION
ACKNOWLEDGMENT
4.2 Transcultural Psychiatry
ETHNOCULTURAL DIVERSITY OF THE U.S. POPULATION
RACISM AND MENTAL HEALTH
MENTAL HEALTH OF RACIAL, ETHNIC, AND MIGRANT POPULATIONS
MENTAL HEALTH CARE DISPARITIES FOR MIGRANT AND MINORITIZED ETHNORACIAL POPULATIONS
MENTAL HEALTH OF INDIGENOUS PEOPLES OF THE UNITED STATES
MENTAL HEALTH OF REFUGEES
CULTURE AND MENTAL HEALTH
CULTURALLY COMPETENT ASSESSMENT AND TREATMENT
GLOBAL PERSPECTIVE ON MENTAL HEALTH
4.3 Evolutionary Foundations for Psychiatric Research and Practice
FIVE ADVANCES
CORE PRINCIPLES OF EVOLUTIONARY BIOLOGY
BEHAVIORAL ECOLOGY
EMOTIONS
RELATIONSHIPS
EXPLAINING VULNERABILITY TO SPECIFIC DISORDERS
FUTURE DIRECTIONS
ACKNOWLEDGMENT
5 Quantitative and Experimental Methods in Psychiatry
5.1 Quantitative and Experimental Methods in Psychiatry: Epidemiology
BACKGROUND
MEASURES OF DISEASE FREQUENCY
MEASURES OF EFFECT AND ASSOCIATION
EPIDEMIOLOGIC STUDY DESIGNS
SAMPLING AND SAMPLING STRATEGIES
MEASUREMENT
CASE IDENTIFICATION
ASSESSMENT INSTRUMENTS USED IN EPIDEMIOLOGIC STUDIES OF MENTAL DISORDERS
MAJOR EPIDEMIOLOGIC SURVEYS
EMERGING ISSUES
5.2 Statistics and Experimental Design
BASIC IDEAS
USING DATA TO ESTIMATE PARAMETERS
USING DATA TO TEST HYPOTHESES
THE BAYESIAN APPROACH
RANDOMIZED CLINICAL TRIALS
SPECIFIC STATISTICAL METHODS
STUDY DESIGN
EVALUATING TREATMENTS UNDER CONTROLLED CONDITIONS, IN THE REAL WORLD, AND UNDER FINANCIAL CONSTRAINTS
ACKNOWLEDGMENT
6 Theories of Personality and Psychopathology
6.1 Psychoanalytic Theories and Treatment: Perspective from North America and Great Britain
SIGMUND FREUD
EGO PSYCHOLOGY
MARGARET MAHLER’S DEVELOPMENTAL MODEL
OBJECT RELATIONS THEORY
HEINZ KOHUT’S SELF-PSYCHOLOGY
OTTO KERNBERG’S INTEGRATION OF OBJECT RELATIONS AND STRUCTURAL SCHOOLS
ATTACHMENT THEORY
RELATIONAL THEORY AND INTERSUBJECTIVE APPROACH
NEUROPSYCHOANALYSIS
PSYCHOANALYTIC THEORY IN PRACTICE
TECHNICAL ASPECTS
CONCLUDING REFLECTIONS
6.2 Erik H. Erikson
CHILDHOOD AND ADOLESCENCE
BECOMING A CHILD PSYCHOANALYST
EMIGRATING TO AMERICA
PSYCHOANALYTIC ANTHROPOLOGY
MIDLIFE TRANSITION
EIGHT STAGES OF THE LIFE CYCLE
BECOMING A BIOGRAPHER OF YOUTH
BECOMING A BIOGRAPHER OF MIDDLE AGE
ERIKSON AND CULTURE
APPLICATION OF ERIKSON’S CONCEPTS TO CLINICAL WORK
6.3 Other Psychodynamic Schools
ADOLF MEYER
ALFRED ADLER
CARL GUSTAV JUNG
FRANZ ALEXANDER
WILHELM REICH
KAREN HORNEY
ERICH FROMM
HARRY STACK SULLIVAN
ERIC BERNE
NANCY CHODOROW
6.4 Approaches Derived from Philosophy and Psychology
PHILOSOPHY
BEHAVIORAL AND SOCIAL LEARNING APPROACHES
HUMANISTIC APPROACHES
TRAIT AND FACTOR MODELS
ACKNOWLEDGMENT
7 Diagnosis and Psychiatry: Examination of the Psychiatric Patient
7.1 Psychiatric Interview, History, and Mental Status Examination of the Adult Patient
GENERAL PRINCIPLES
HISTORY AND EXAMINATION
COMMUNICATION OF OPINIONS AND RECOMMENDATIONS
TECHNIQUES
SELECTED CHALLENGING INTERVIEW SCENARIOS
SPECIAL TOPICS
7.2 The Psychiatric Report and Outline for a Psychiatric Examination
PSYCHIATRIC HISTORY
MENTAL STATUS
FURTHER DIAGNOSTIC STUDIES
SUMMARY OF FINDINGS
DIAGNOSIS
PROGNOSIS
PSYCHODYNAMIC FORMULATION
COMPREHENSIVE TREATMENT PLAN
7.3 Practice Guidelines in Psychiatry
EARLY GUIDELINE EFFORTS
AMERICAN MEDICAL ASSOCIATION AND GUIDELINES
INSTITUTE OF MEDICINE REPORTS
PRACTICE GUIDELINES IN PSYCHIATRY
APA PRACTICE GUIDELINE PROJECT
ADVANTAGES AND LIMITATIONS OF GUIDELINES
THE FUTURE OF PRACTICE GUIDELINES
7.4 Neuropsychological Assessment of Adults
NEUROPSYCHOLOGICAL ASSESSMENT OF ADULTS
WHO IS A CLINICAL NEUROPSYCHOLOGIST?
RELATIONSHIP TO OTHER DISCIPLINES
HISTORICAL INFLUENCES
NEUROANATOMICAL CORRELATES
PSYCHOMETRIC ISSUES
GENERAL REFERRAL ISSUES
APPROACHES TO NEUROPSYCHOLOGICAL ASSESSMENT
DOMAINS OF FORMAL NEUROPSYCHOLOGICAL ASSESSMENT
THERAPEUTIC DISCUSSION OF RESULTS
7.5 Personality Assessment of Adults
PURPOSES OF PSYCHOLOGICAL TESTING
PSYCHOMETRIC PROPERTIES OF PERSONALITY ASSESSMENT INSTRUMENTS
ADULT PSYCHOLOGICAL TESTS
7.6 Medical Assessment and Laboratory Testing in Psychiatry
PHYSICAL HEALTH MONITORING
DIAGNOSTIC ASSESSMENT
TREATMENT SELECTION AND MONITORING
CONCLUSION
7.7 Principles and Applications of Quantitative Electroencephalography in Psychiatry
DEDICATION
FROM EEG TO qEEG
NEUROMETRIC qEEG: HOMEOSTATIC REGULATION OF THE EEG FREQUENCY SPECTRUM
STEPS IN NEUROMETRIC qEEG ANALYSIS
HOMEOSTATIC SYSTEM GENERATING AND REGULATING THE EEG
qEEG Source Localization Tomographic Brain Images
CLINICAL APPLICATIONS OF qEEG DEPARTURES FROM GROUND STATE OR DEFAULT MODE NETWORK
qEEG-Based Depth of Anesthesia Monitor: Level of Consciousness
THERAPEUTIC CORRECTION OF DEPARTURES FROM THE GROUND STATE
CONSCIOUSNESS
INFORMATION IS SYNCHRONOUS DEVIATIONS FROM GROUND STATE
CONCLUSIONS
7.8 Psychiatric Rating Scales
POTENTIAL BENEFITS AND LIMITATIONS OF RATING SCALES IN PSYCHIATRY
TYPES OF SCALES AND WHAT THEY MEASURE
ASSESSMENT OF RATING SCALES
SELECTION OF PSYCHIATRIC RATING SCALES
7.9 Electronic Media in Psychiatry
DEFINITIONS AND LEGISLATIVE HISTORY
COMMUNICATION EVOLUTION
MEDICAL RECORDS
CLINICAL ISSUES
ETHICAL ISSUES
THEORETICAL ISSUES
RESEARCH AND EVALUATION
7.10 Cultural Competency in the Organization and Delivery of Psychiatric Care
DEFINITIONS: CULTURAL GROUP; CULTURAL COMPETENCY
STRUCTURAL COMPETENCY: ADDRESSING INSTITUTIONAL DRIVERS OF INEQUALITY
WHY CC IS IMPORTANT: DIVERSITY, DISPARITIES
CULTURAL AWARENESS OF CAREGIVERS
GOVERNMENT RESPONSE: STANDARDS, REGULATIONS, AND LEGAL REQUIREMENTS
BEYOND THE RHETORIC: DEFINING THE ACTUAL ACTIVITIES OF CC
IN CONCLUSION
7.11 Medical Error
PREVENTING MEDICAL ERROR
8 Clinical Manifestations of Psychiatric Disorders
NEED FOR A COMPREHENSIVE CLINICAL PERSPECTIVE
THE CLINICAL CHALLENGES
DISTINGUISHING FEATURES OF PSYCHIATRIC SIGNS AND SYMPTOMS
THINKING DISTURBANCES
DISTURBANCES OF JUDGMENT
DISTURBANCES OF PERCEPTION
DISTURBANCES OF CONSCIOUSNESS
DISTURBANCES OF THE SELF
DISTURBANCES OF MEMORY
LANGUAGE DISORDERS
DISORDERS OF THE WILL
DISTURBANCES OF MOOD
ANXIETY DISORDERS
SOMATIC DISTURBANCES IN PSYCHIATRIC ILLNESS
DISTURBANCES OF BEHAVIOR
DISTURBANCES OF INTERPERSONAL RELATIONSHIPS
DISTURBANCES IN MOTOR ACTIVITY
MOTOR DISTURBANCES AND MOVEMENT DISORDERS
DRUG-INDUCED MOVEMENT DISORDERS
MOTOR DISTURBANCES OF SCHIZOPHRENIA
OTHER MOVEMENT DISTURBANCES
FUTURE PERSPECTIVES
ACKNOWLEDGMENTS
9 Classification in Psychiatry
9.1 Present and Future of Classification Systems for Mental Disorders
CLASSIFICATION IN MEDICINE
BRIEF GLOSSARY
DEFINITION OF MENTAL DISORDER (DSM-5)
BRIEF HISTORY OF PSYCHIATRIC DIAGNOSIS
CLASSICAL EUROPEAN PSYCHOPATHOLOGY
THE U.S. CLASSIFICATION SYSTEMS LEADING TO DSM-5
INTERNATIONAL CLASSIFICATION OF DISEASES
EVOLUTION OF MODERN PSYCHIATRIC NOSOLOGY IN THE UNITED STATES
MODERN PSYCHIATRIC CLASSIFICATIONS IN NORTH AMERICA
9.2 The Classification of Mental Disorders in the International Classification of Diseases (ICD-11)
THE INTERNATIONAL CLASSIFICATION OF DISEASES
COMPARING ICD AND DSM CLASSIFICATIONS
MENTAL DISORDERS IN ICD-11
ICD-11 AND DSM-5: SOME CONTROVERSIES
SUMMARY AND CONCLUSIONS
10 Neurocognitive Disorders
10.1 Cognitive Disorders: Introduction
10.2 Delirium
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
ETIOLOGIES
DIAGNOSIS
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
PREVENTION
TREATMENT
10.3 Major Neurocognitive Disorders (Dementia)
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
LABORATORY EXAMINATION AND PATHOLOGY
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
MANAGEMENT
HEALTH DISPARITIES IN DEMENTIA
COVID-19 AND DEMENTIA
MAJOR NEUROCOGNITIVE DISORDER SUBTYPES
10.4 Mild Cognitive Impairment and Amnestic Disorders
MILD COGNITIVE IMPAIRMENT
FUTURE DIRECTIONS
AMNESTIC DISORDERS
10.5 Cognitive Disorders Due to Another Medical Condition or Substance
NOSOLOGY
ETIOLOGY
DIAGNOSTIC AND CLINICAL FEATURES
COURSE AND PROGNOSIS
TREATMENT
SPECIFIC DISORDERS
ACKNOWLEDGMENT
11 Substance-Related Disorders
11.1 Substance Use Disorders: Introduction
SUMMARY
11.2 Alcohol-Related Disorders
DEFINITION AND COMPARATIVE NOSOLOGY
A Brief History of Alcohol and AUDs
EPIDEMIOLOGY
PHARMACOLOGY AND ALCOHOL’S EFFECTS
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
IDENTIFICATION IN CLINICAL SETTINGS AND RELATED LABORATORY TESTS
DIFFERENTIAL DIAGNOSIS
Course and Prognosis of AUDs
TREATMENT
11.3 Stimulant-Related Disorders
DEFINITIONS
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
COMORBIDITY
TOXICITY AND MEDICAL COMPLICATIONS
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
11.4 Caffeine-Related Disorders
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
CAFFEINE INTOXICATION
CAFFEINE-INDUCED ANXIETY DISORDER
CAFFEINE-INDUCED SLEEP DISORDER
CAFFEINE WITHDRAWAL
CAFFEINE USE DISORDER
11.5 Cannabis-Related Disorders
HISTORY
CANNABIS PREPARATIONS
METHODS OF USE
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY OF CANNABIS USE
PHARMACOLOGY OF CANNABINOIDS
DIAGNOSTIC AND CLINICAL FEATURES
ADVERSE EFFECTS OF CANNABIS USE
LABORATORY EXAMINATIONS
TREATMENT
CONCLUSION
11.6 Hallucinogen-Related Disorders
HISTORICAL OVERVIEW
EPIDEMIOLOGIC OVERVIEW OF HALLUCINOGEN USE
HALLUCINOGEN SUBCLASSES
COMPARATIVE NOSOLOGY
PHENCYCLIDINE AND OTHER HALLUCINOGEN INTOXICATION
PHENCYCLIDINE USE DISORDER AND OTHER HALLUCINOGEN USE DISORDER
HALLUCINOGEN-PERSISTING PERCEPTION DISORDER
PCP- AND OTHER HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER
PHENCYCLIDINE- AND OTHER HALLUCINOGEN-INDUCED BIPOLAR DISORDER
PHENCYCLIDINE- AND OTHER HALLUCINOGEN-INDUCED DEPRESSIVE DISORDER
PHENCYCLIDINE- AND OTHER HALLUCINOGEN-INDUCED ANXIETY DISORDER
PHENCYCLIDINE- AND OTHER HALLUCINOGEN-INDUCED INTOXICATION DELIRIUM
UNSPECIFIED PHENCYCLIDINE-RELATED DISORDER AND UNSPECIFIED HALLUCINOGEN-RELATED DISORDER
11.7 Inhalant-Related Disorders
DEFINITION
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
PHARMACOLOGY AND TOXICOLOGY
DIAGNOSIS AND CLINICAL FEATURES
INHALANT USE DISORDER
INHALANT-INDUCED PSYCHIATRIC DISORDERS
ADDITIONAL INHALANT CLASSIFICATIONS
FUTURE DIRECTIONS
11.8 Tobacco-Related Disorders
HISTORY
COMPARATIVE NOSOLOGY AND DIAGNOSTIC FEATURES
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
SPECIAL POPULATIONS
EMERGING AREAS OF RESEARCH
PREVENTION AND POLICY INITIATIVES
11.9 Opioid Use and Related Disorders: From Neuroscience to Treatment
HISTORICAL BACKGROUND
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY AND PATHOGENESIS
DIAGNOSIS AND CLINICAL FEATURES
COURSE AND PROGNOSIS
TREATMENT
CONCLUSION
11.10 Sedative-, Hypnotic-, or Anxiolytic-Related Disorders
DEFINITION
ETIOLOGY AND NEUROPHARMACOLOGY
MISUSE LIABILITY
EPIDEMIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
TREATMENT
11.11 Anabolic-Androgenic Steroid-Related Disorders
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
PHARMACOLOGY
LABORATORY FINDINGS
ETIOLOGY
ANABOLIC STEROID DEPENDENCE
ANABOLIC STEROID–INDUCED MOOD DISORDERS
ANABOLIC STEROID–INDUCED PSYCHOTIC DISORDER
ANABOLIC STEROID–RELATED DISORDER NOT OTHERWISE SPECIFIED
12 Schizophrenia and Other Psychotic Disorders
12.1 Introduction and Overview
12.2 Phenomenology of Schizophrenia
DIAGNOSTIC CRITERIA
SYMPTOMS OF SCHIZOPHRENIA
RESEARCH IMPLICATIONS
12.3 Global Burden of Schizophrenia
SCHIZOPHRENIA BEFORE AND AFTER KRAEPELIN
DIAGNOSTIC COMPARABILITY OF THE SCHIZOPHRENIA PHENOTYPE ACROSS POPULATIONS
VARIATIONS IN THE INCIDENCE AND PREVALENCE OF SCHIZOPHRENIA
VARIATION IN THE COURSE AND OUTCOME OF SCHIZOPHRENIA
THE BURDEN OF COMORBIDITY
VARIATIONS IN MORTALITY
CRIMINAL OFFENDING AND VICTIMIZATION
CLINICAL HIGH-RISK FOR PSYCHOSIS AND SUBTHRESHOLD PSYCHOTIC EXPERIENCES
SOCIAL AND ECONOMIC COSTS
FUTURE DIRECTIONS
12.4 Genetics of Schizophrenia
FAMILY, TWIN, AND ADOPTION STUDIES
ADVANCES IN THE MOLECULAR GENETICS OF SCHIZOPHRENIA
CONVERGENCE ONTO BIOLOGIC MECHANISMS
THE EMERGING GENETIC ARCHITECTURE OF SCHIZOPHRENIA
NEURODEVELOPMENTAL SPECTRUM
CLINICAL IMPLICATIONS
12.5 The Clinical Epidemiology of Psychosis Spectrum Disorder
WHAT IS CLINICAL EPIDEMIOLOGY?
RISK FACTORS FOR THE ONSET OF PSYCHOSIS SPECTRUM DISORDER
SPECIFICITY OF HERITABILITY
GENETIC MODEL OF LIABILITY FOR PSYCHOSIS SPECTRUM DISORDER
RISK FACTORS OPERATING DURING CHILDHOOD AND ADOLESCENCE
STRESSFUL LIFE EVENTS AND EARLY CHILDHOOD ADVERSITY
PREMORBID VULNERABILITY INDICATORS/MARKERS
HIGH-RISK MODELS OF PSYCHOSIS ONSET
THE COURSE AND OUTCOME OF PSYCHOSIS SPECTRUM DISORDER
TOWARD AN EMPIRICALLY BASED MODEL OF PSYCHOSIS SPECTRUM DISORDER: A WORK IN PROGRESS
12.6 Cellular and Molecular Neuropathology of Schizophrenia
MORPHOMETRIC STUDIES AND CYTOARCHITECTURAL CHANGES
NEUROTRANSMITTER SYSTEMS
BIOENERGETIC DYSFUNCTION
SCHIZOPHRENIA AS A NEURODEVELOPMENTAL DISORDER
THE INFLAMMATION HYPOTHESIS
INTEGRATIVE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
12.7 Structural Brain Imaging in Schizophrenia
THE BRAIN AND SCHIZOPHRENIA: HISTORICAL PERSPECTIVE
OVERVIEW OF CHAPTER
FUTURE DIRECTIONS FOR STRUCTURAL BRAIN IMAGING IN SCHIZOPHRENIA
12.8 Functional Brain Imaging in Schizophrenia
MAGNETIC RESONANCE FUNCTIONAL IMAGING METHODS
FUNCTIONAL MAGNETIC RESONANCE IMAGING IN SCHIZOPHRENIA
12.9 Molecular Brain Imaging in Schizophrenia
MOLECULAR BRAIN IMAGING AND THEORIES OF SCHIZOPHRENIA
TYPES OF MOLECULAR IMAGING
MOLECULAR IMAGING IN PATHOPHYSIOLOGY
MOLECULAR IMAGING IN DRUG DEVELOPMENT FOR TREATMENTS IN SCHIZOPHRENIA
ISSUES OF QUANTIFICATION OF NEURORECEPTORS, TRANSPORTERS, AND INTRASYNAPTIC NEUROTRANSMITTERS
MOLECULAR IMAGING AND GENETICS
ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SCHIZOPHRENIA SUBTYPING AND HETEROGENEITY ANALYSIS
MOLECULAR IMAGING IN CLINICAL PRACTICE
FUTURE DIRECTIONS
12.10 Neurocognition in Schizophrenia
NEUROCOGNITIVE IMPAIRMENT IN SCHIZOPHRENIA
NATURAL HISTORY OF NEUROCOGNITIVE IMPAIRMENT
RELATIONSHIP OF NEUROCOGNITIVE IMPAIRMENT TO SCHIZOPHRENIA SYMPTOMS
CLINICAL IMPORTANCE OF NEUROCOGNITIVE IMPAIRMENT
NEUROCOGNITION AND FUNCTIONAL CAPACITY
TREATMENT OF NEUROCOGNITIVE IMPAIRMENT
METHODS OF ASSESSMENT
12.11 Phenotypes of Psychosis
DO CLINICAL EXPERIENTIAL PSYCHOSIS DEFINITIONS CAPTURE BIOLOGIC REALITY?
NEUROBIOLOGY OF DSM PSYCHOSIS DIAGNOSES
HYPOTHESIS TESTING AND REPLICATION IN PSYCHOLOGY AND PSYCHIATRY
B-SNIP RESULTS USING DSM PSYCHOSIS DIAGNOSES AS THE GOLD STANDARD
PSYCHOSIS BIOTYPES
PSYCHOSIS SYNDROMES: DIFFERENCES IN KIND?
12.12 Schizophrenia: Pharmacologic Treatment
HISTORY
PHASES OF TREATMENT IN SCHIZOPHRENIA
FIRST EPISODE SCHIZOPHRENIA
EFFECTIVENESS OF DRUGS FOR PSYCHOSIS
TREATMENT OF ACUTE EPISODES
MANAGING SIDE EFFECTS
NEGATIVE, MOOD, AND COGNITIVE SYMPTOMS
SUICIDAL BEHAVIOR
STRATEGIES FOR POOR RESPONDERS
MAINTENANCE THERAPY
INTEGRATING PHARMACOTHERAPY AND PSYCHOSOCIAL TREATMENT
DRUG DEVELOPMENT FOR SCHIZOPHRENIA
12.13 Psychiatric Rehabilitation
HISTORY
OVERVIEW OF TECHNIQUES
SUPPORTIVE HOUSING
INDIVIDUAL PLACEMENT AND SUPPORT
TECHNOLOGY TOOLS
SUMMARY
12.14 Medical Health in Schizophrenia
ALL-CAUSE MORTALITY IN SCHIZOPHRENIA
MEDICAL CAUSES OF EXCESS MORTALITY IN SCHIZOPHRENIA
MECHANISMS OF DISEASE
INCREASED PREVALENCE OF MODIFIABLE RISK FACTORS IN PATIENTS WITH SCHIZOPHRENIA
PRIMARY AND SECONDARY PREVENTION
SUMMARY AND RECOMMENDATIONS
ACKNOWLEDGMENTS
12.15 Recovery in Schizophrenia
DEFINING RECOVERY AND ITS EVOLUTION
JOURNEY OF RECOVERY
RECOVERY OUTCOMES
EVIDENCE-BASED PRACTICES
EXEMPLARY PRACTICES
ROLE OF PSYCHIATRIST
PEER SUPPORT SPECIALIST
12.16 Psychosis as a Defining Dimension in Schizophrenia
DSM-5: DEFINITION OF PSYCHOSIS
CATEGORICAL AND DIMENSIONAL DIAGNOSTIC APPROACHES IN SCHIZOPHRENIA
PSYCHOSIS SPECTRUM DISORDERS: DOES PSYCHOSIS CUT ACROSS THE FORMAL DIAGNOSTIC CATEGORIES?
BIOLOGIC FACTORS IN PSYCHOSIS: EVIDENCE FROM TRANSLATIONAL NEUROSCIENCE INVESTIGATIONS
PSYCHOSIS AS A CLINICAL CONTINUUM: FROM ATTENUATED PSYCHOSIS PHENOTYPES TO FRANK PSYCHOTIC DISORDERS
ACKNOWLEDGMENTS
12.17 Other Psychotic Disorders
ACUTE AND TRANSIENT PSYCHOTIC DISORDER AND BRIEF PSYCHOTIC DISORDER
SCHIZOPHRENIFORM DISORDER
DELUSIONAL DISORDER
SCHIZOAFFECTIVE DISORDER
SUBSTANCE/MEDICATION-INDUCED PSYCHOTIC DISORDER
PSYCHOTIC DISORDER DUE TO ANOTHER MEDICAL CONDITION
CATATONIA
OTHER SPECIFIED SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDER AND UNSPECIFIED SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDER
ATTENUATED PSYCHOSIS SYNDROME
DELUSIONAL SYMPTOMS IN PARTNER OF INDIVIDUAL WITH DELUSIONAL DISORDER
13 Mood Disorders
13.1 Mood Disorders: Historical Introduction and Conceptual Overview
CLINICAL AND PUBLIC HEALTH SCOPE OF MOOD DISORDERS
DEFINITIONS
ANCIENT GREEK AND ROMAN DESCRIPTIONS
MODERN ERA
CONTEMPORARY MODELS OF DEPRESSION
THEORETICAL SYNTHESIS
ACKNOWLEDGMENT
13.2 Mood Disorders: Epidemiology
DESCRIPTIVE EPIDEMIOLOGY
CORRELATES OF MOOD DISORDERS
SOCIAL CORRELATES
PSYCHOSOCIAL FACTORS
COMORBIDITY
SERVICE PATTERNS
IMPACT OF MOOD DISORDERS
HISTORICAL TRENDS
13.3 Mood Disorders: Clinical Features
TERMINOLOGY
RECENT DIAGNOSTIC TRENDS
SPECTRUM OF MOOD DISORDERS
AFFECTS, MOODS, TEMPERAMENTS, AND THE MORBID MOOD STATES
PSYCHOPATHOLOGY
DIAGNOSTIC CLASSIFICATION
DEPRESSIVE DISORDERS
BIPOLAR DISORDERS
UNSPECIFIED MOOD DISORDERS
DIFFERENTIAL DIAGNOSIS
ACKNOWLEDGMENT
13.4 Mood Disorders: Intrapsychic and Interpersonal Aspects
PSYCHODYNAMIC ASPECTS OF MOOD DISORDERS
PSYCHOANALYTIC DESCRIPTIONS OF MAJOR DEPRESSION
PSYCHOANALYTIC FORMULATIONS OF DYSTHYMIA
SYNTHESIS: DYNAMICS OF DEPRESSION
PSYCHOANALYTIC FORMULATIONS OF MANIA
COGNITIVE THEORY OF DEPRESSION
INTERPERSONAL THEORY OF DEPRESSION
13.5 Mood Disorders: Suicidal Behavior
FROM SUICIDE RISK ASSESSMENT TO SUICIDE RISK FORMULATION
EXPLORATION OF SUICIDE RISK IN MOOD DISORDERS: DATA FROM PSYCHOLOGICAL AUTOPSIES
CLINICALLY DETECTABLE SUICIDE RISK AND PROTECTIVE FACTORS IN PATIENTS WITH MOOD DISORDERS
SUICIDAL RISK EMERGING DURING ANTIDEPRESSANT TREATMENT: THE ROLE OF UNDERLYING BIPOLARITY
PREVENTION OF SUICIDE IN PATIENTS WITH MOOD DISORDERS
13.6 Mood Disorders: Pharmacologic Treatment of Depression and Bipolar Disorders
TREATMENT OF MAJOR DEPRESSIVE DISORDER—FOCUS ON PSYCHOPHARMACOLOGY
TREATMENT OF BIPOLAR DISORDERS
FUTURE DIRECTIONS IN THE TREATMENT OF MOOD DISORDERS
13.7 Mood Disorders: Psychotherapy
HISTORY OF PSYCHOTHERAPY FOR DEPRESSION
REVIEW OF RESEARCH FINDINGS
APPLYING THE RESEARCH TO CLINICAL PRACTICE
TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH CBT
ADJUNCTIVE PSYCHOTHERAPY FOR BIPOLAR DISORDER
FUTURE DIRECTIONS
13.8 Mood Disorders: Neurobiology
CLINICAL PHENOMENOLOGY
RISK FACTORS
ETIOLOGY OF EMOTIONS
EMOTIONAL PROCESSING AND THE BRAIN
STRESS AND ANIMAL MODELS OF DEPRESSION
MALTREATMENT AND EARLY ADVERSITY
MONOAMINE SYSTEMS: FUNCTION AND DYSFUNCTION
NORADRENERGIC SYSTEMS
SEROTONINERGIC SYSTEMS
DOPAMINERGIC SYSTEMS
SUMMARY OF RESEARCH ON MONOAMINES IN DEPRESSION
OTHER NEUROTRANSMITTER DISTURBANCES
NEUROPLASTICITY AND NEUROTROPHIC CHANGES IN MOOD DISORDERS
SECOND MESSENGERS AND INTRACELLULAR CASCADES
ALTERATIONS OF HORMONAL REGULATION
GROWTH HORMONE (GH)
ALTERATIONS OF SLEEP NEUROPHYSIOLOGY
STRUCTURAL AND FUNCTIONAL BRAIN IMAGING
IMMUNOLOGIC DISTURBANCE
SUMMARY
14 Anxiety Disorders
14.1 Anxiety Disorders: Introduction and Overview
BACKGROUND ON FEAR AND ANXIETY
DSM-5 MODIFICATIONS IN ANXIETY DISORDERS
ASSESSMENT OF ANXIETY
OVERVIEW OF ANXIETY DISORDERS SECTION
14.2 Clinical Features of the Anxiety Disorders
PANIC DISORDER AND THE PANIC ATTACK SPECIFIER
AGORAPHOBIA
SOCIAL ANXIETY DISORDER
SPECIFIC PHOBIA
GENERALIZED ANXIETY DISORDER
SELECTIVE MUTISM
SEPARATION ANXIETY DISORDER
SUBSTANCE/MEDICATION-INDUCED ANXIETY DISORDER AND ANXIETY DISORDER DUE TO ANOTHER MEDICAL CONDITION
FUTURE DIRECTIONS
14.3 Epidemiology of Anxiety Disorders
BACKGROUND: PSYCHIATRIC EPIDEMIOLOGY
MAGNITUDE OF ANXIETY DISORDERS
CORRELATES AND RISK FACTORS
COURSE AND PERSISTENCE
IMPACT OF ANXIETY DISORDERS
FUTURE DIRECTIONS
14.4 Anxiety Disorders: Neurobiology and Neuroscience
NEUROCHEMICAL BASIS OF FEAR AND ANXIETY
NORADRENERGIC SYSTEM
HYPOTHALAMIC–PITUITARY–ADRENAL AXIS
CORTICOTROPIN-RELEASING HORMONE
DOPAMINERGIC SYSTEM
SEROTONERGIC SYSTEM
γ-Amino Butyric Acid and the Benzodiazepine System
GLUTAMATE SYSTEM
NEUROSTEROIDS
ARGININE VASOPRESSIN
OXYTOCIN
NEUROPEPTIDE Y
GALANIN
CHOLECYSTOKININ
ENDOCANNABINOID SYSTEM
INFLAMMATORY AND IMMUNOLOGIC FACTORS
FUTURE DIRECTIONS
14.5 Neuroimaging and the Neuroanatomical Circuits Implicated in Anxiety Disorders
BRIDGING FROM PHENOMENOLOGY TO NEUROCIRCUITRY
PRECLINICAL STUDIES OF FEAR LEARNING
ANATOMICAL CORRELATES OF FEAR AND ANXIETY
OVERVIEW OF NEUROIMAGING TECHNOLOGY
HUMAN NEUROIMAGING STUDIES OF FEAR CONDITIONING AND EXTINCTION
COGNITIVE AND EMOTIONAL ACTIVATION PROBES
NEUROIMAGING STUDIES OF ANXIETY DISORDERS
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
14.6 Anxiety Disorders: Cognitive-Behavioral Therapy
ASPECTS OF THE ANXIETY DISORDERS PARTICULARLY RELEVANT TO CBT
EMOTIONAL PROCESSING THEORY: A PSYCHOLOGICAL MODEL OF ANXIETY DISORDERS AND THEIR TREATMENT
COGNITIVE-BEHAVIORAL THERAPY PROCEDURES FOR ANXIETY DISORDERS
14.7 Somatic Therapies for Anxiety Disorders
PRINCIPLES OF MANAGEMENT
PHARMACOLOGIC OPTIONS FOR TREATING ANXIETY DISORDERS
TREATMENT RESPONSE AND COURSE OF ILLNESS ACROSS ANXIETY DISORDERS
MANAGEMENT OF INDIVIDUAL ANXIETY CONDITIONS
TREATMENT OF ANXIETY DISORDERS IN CHILDREN AND ADOLESCENTS
SUMMARY
15 Obsessive-Compulsive and Related Disorders
OBSESSIVE-COMPULSIVE DISORDER
BODY DYSMORPHIC DISORDER
HOARDING DISORDER
TRICHOTILLOMANIA (HAIR-PULLING DISORDER)
EXCORIATION (SKIN-PICKING) DISORDER
OCRD DUE TO ANOTHER MEDICAL DISORDER
SUBSTANCE/MEDICATION-INDUCED OCRD
OTHER SPECIFIED AND UNSPECIFIED OCRDS
CONCLUSION
16 Pathological and Problem Gambling: Gambling Disorder
HISTORICAL BACKGROUND
NOSOLOGIC CONSIDERATIONS
EPIDEMIOLOGY
FAMILY HISTORY
CLINICAL FEATURES
COMORBIDITY
DIFFERENTIAL DIAGNOSIS
ETIOLOGY
MATERIALIST RESEARCH AND HYPOTHESES
TREATMENT
GAMBLING AND THE LAW
THE FUTURE
THE NATIONAL COUNCIL ON PROBLEM GAMBLING
CLINICAL VIGNETTES
17 Post-Traumatic Stress Disorder
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
IMPLICATIONS AND FUTURE DIRECTIONS
18 Somatic Symptom and Related Disorders
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
SPECIFIC SOMATIC SYMPTOM AND RELATED DISORDERS
GENERAL GUIDELINES FOR TREATMENT OF SOMATIC SYMPTOM DISORDERS
THE FUTURE OF SOMATIC SYMPTOM DISORDERS—TOWARD A NEW DIAGNOSTIC CLASSIFICATION?
19 Factitious Disorder
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT AND MANAGEMENT
FUTURE DIRECTIONS
20 Dissociative Disorders
HISTORY
DISSOCIATIVE DISORDERS, MODERN SOCIETY, AND THE MEDIA
COMPARATIVE NOSOLOGY
DSM-5 (AND TR) DIAGNOSTIC CRITERIA FOR THE DISSOCIATIVE DISORDERS
VALIDITY OF THE DISSOCIATIVE DISORDERS
EPIDEMIOLOGY OF THE DISSOCIATIVE DISORDERS
GENERAL POPULATION STUDIES OF DISSOCIATIVE DISORDERS
STUDIES OF DISSOCIATIVE DISORDERS IN CLINICAL POPULATIONS
GENETICS AND DISSOCIATION
NEUROBIOLOGY OF DISSOCIATION AND DISSOCIATIVE DISORDERS
ETIOLOGY OF DISSOCIATION AND DISSOCIATIVE DISORDERS
DISSOCIATIVE IDENTITY DISORDER
DEPERSONALIZATION/DEREALIZATION DISORDER
OTHER SPECIFIED DISSOCIATIVE DISORDERS
EXAMPLE 1: ATYPICAL PRESENTATIONS NOT MEETING FULL DIAGNOSTIC CRITERIA FOR DISSOCIATIVE IDENTITY DISORDER
COERCIVE PERSUASION
ACUTE DISSOCIATIVE REACTIONS TO STRESSFUL EVENTS
DISSOCIATIVE TRANCE DISORDER
21 Normal Sexuality and Sexual Disorders
21.1 Normal Human Sexuality and Sexual Dysfunctions
NORMAL SEXUALITY
BIOLOGIC DIFFERENCES BETWEEN THE SEXES
PSYCHOSEXUALITY
SEXUAL LEARNING AND SEXUAL BEHAVIOR
LOVE AND INTIMACY
DESIRE, INTEREST, AND AROUSAL DISORDERS
PAIN DISORDER
SUBSTANCE/MEDICATION-INDUCED SEXUAL DYSFUNCTION
TREATMENT
CULTURAL MORES AND SEXUALITY
21.2 Homosexuality, Gay and Lesbian Identities, and Homosexual Behavior
DEFINITIONS
THEORIES
PREVALENCE
ORIGINS OF HOMOSEXUALITY
LIFE STAGE AND CULTURAL ISSUES
CLINICAL APPROACHES
ETHICAL AND LEGAL ISSUES
TRAINING AND RESEARCH NEEDS
INTERNET RESOURCES
21.3 Paraphilic Disorders
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT BACKGROUND
MODELS OF TREATMENT
ETHICAL AND LEGAL CONSIDERATIONS
FUTURE DIRECTIONS
21.4 Gender Identity, Gender Diversity, Gender Dysphoria/Incongruence
DEFINITIONS
THEORIES
FREQUENCY
DIAGNOSIS
ORIGINS OF GENDER DYSPHORIA
SOCIAL AND CULTURAL ISSUES
CLINICAL APPROACHES
ETHICAL AND LEGAL ISSUES
TRAINING AND RESEARCH NEEDS
INTERNET RESOURCES
21.5 Sexual Addiction
DIAGNOSIS AND RELATED MATTERS
THE ADDICTIVE PROCESS
SELECTION OF SEXUAL BEHAVIOR
TREATMENT
ACKNOWLEDGMENT
22 Feeding and Eating Disorders
DEFINITIONS
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
23 Sleep Disorders
OVERVIEW
SLEEP DISORDERS CLASSIFICATIONS
INSOMNIA DISORDER
HYPERSOMNOLENCE DISORDER
NARCOLEPSY
SLEEP-RELATED BREATHING DISORDERS
CIRCADIAN RHYTHM SLEEP–WAKE DISORDERS
PARASOMNIAS (AND SLEEP-RELATED MOVEMENT DISORDERS)
SUBSTANCE/MEDICATION-INDUCED SLEEP DISORDER
TOOLS IN SLEEP MEDICINE
SLEEP DISORDERS CASES
SUMMARY
24 Impulse-Control Disorders
24.1 Intermittent Explosive Disorder
DIAGNOSIS AND EPIDEMIOLOGY
ETIOLOGY
TREATMENT
24.2 Pyromania
DIAGNOSIS AND EPIDEMIOLOGY
ETIOLOGY
TREATMENT
24.3 Kleptomania
DIAGNOSIS AND EPIDEMIOLOGY
ETIOLOGY
TREATMENT
25 Adjustment Disorders
COMPARATIVE NOSOLOGY: DSM
HISTORY
DSM-5
DEFINITION
STRESSOR CRITERIA
SYMPTOMS
TEMPORAL COURSE
ICD
RELIABILITY
VALIDITY
CULTURAL PERSPECTIVES
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
FUTURE DIRECTIONS
26 Personality Disorders
THREE INTERACTIVE SYSTEMS OF LEARNING AND ADAPTABILITY
FLUIDITY AND CREATIVITY IN THE DYNAMICS OF PERSONALITY DEVELOPMENT
IMPORTANCE OF SELF-TRANSCENDENCE FOR PERSONALITY DEVELOPMENT AND HEALTH PROMOTION
GENERAL IMPORTANCE OF PERSONALITY ASSESSMENT IN MEDICINE
BASIC DEFINITIONS AND TERMINOLOGY
PERSONALITY: AN INTEGRATED VIEW
ESSENTIALS OF PERSONALITY ASSESSMENT IN CLINICAL PRACTICE
CONCEPTUAL AND PSYCHOMETRIC ISSUES
PERSONALITY DEVELOPMENT: A SELF-ORGANIZING BIOPSYCHOSOCIAL COMPLEX
PERSONALITY DISORDER
INDIVIDUAL PERSONALITY DISORDERS
CLINICAL AND PSYCHOMETRIC ISSUES
PATHOGENESIS OF PERSONALITY DISORDER
TREATMENT
VOLUME II
27 Consultation-Liaison Psychiatry and Psychosomatic Medicine
27.1 History and Current Trends
ANCIENT HISTORY
MODERN HISTORY
HISTORY OF PSYCHOSOMATIC MEDICINE RESEARCH
CURRENT TRENDS
THE CLINICAL PRACTICE OF CONSULTATION-LIAISON PSYCHIATRY
EVALUATION PROCESS IN CONSULTATION-LIAISON PSYCHIATRY
TREATMENTS USED IN CONSULTATION-LIAISON PSYCHIATRY
MENTAL DISORDERS IN PRIMARY CARE
RESEARCH IN PSYCHOSOMATIC MEDICINE
CURRENT PSYCHOSOMATIC MEDICINE RESEARCH
THE FIELD OF PSYCHOSOMATIC MEDICINE AND C-L PSYCHIATRY
ACCESS TO CONSULTATION-LIAISON PSYCHIATRIC CARE: IMPLICATIONS FOR HEALTH POLICY
ACKNOWLEDGMENT
27.2 Cardiovascular Disorders
CAD AND HTN
MYOCARDIAL DISEASE
VALVULAR HEART DISEASE
ELECTRICAL CONDUCTION DISEASE
MASQUERADERS
PSYCHIATRIC SYMPTOM MANAGEMENT OF PATIENTS WITH CARDIAC DISEASE
PSYCHIATRIC SIDE EFFECTS OF CARDIOVASCULAR MEDICATIONS
ACKNOWLEDGMENT
27.3 Gastrointestinal Disorders
INFLAMMATORY BOWEL DISEASE
FUNCTIONAL GI DISORDERS
FUNCTIONAL BOWEL DISORDERS: IRRITABLE BOWEL SYNDROME
FUNCTIONAL ESOPHAGEAL DISORDERS: FUNCTIONAL CHEST PAIN
THE ROLE OF THE PSYCHIATRIST IN MANAGING FUNCTIONAL GI DISORDERS
GENERAL PSYCHIATRIC APPROACH AND MANAGEMENT FOR FUNCTIONAL GI DISORDERS
SPECIFIC PSYCHIATRIC APPROACH AND MANAGEMENT FOR FUNCTIONAL GI DISORDERS
PSYCHOPHARMACOLOGICAL PRINCIPLES AND MANAGEMENT FOR FUNCTIONAL GI DISORDERS
PSYCHOLOGICAL THERAPIES FOR FUNCTIONAL GI DISORDER
CONCLUDING REMARKS
ACKNOWLEDGMENTS
27.4 Psychosomatic Medicine: Obesity
DEFINITION, NOSOLOGY, AND EPIDEMIOLOGY
DIAGNOSIS, CLINICAL FEATURES
COURSE AND PROGNOSIS
PATHOLOGY AND LABORATORY CONSIDERATIONS
ETIOLOGY
PSYCHIATRIC COMORBIDITIES OF OBESITY
TREATMENT
FUTURE DIRECTIONS
27.5 Respiratory Disorders
DEFINITION AND COMPARATIVE NOSOLOGY
ASTHMA
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
INTERSTITIAL LUNG DISEASE
CYSTIC FIBROSIS
RESPIRATORY FAILURE
SOMATOFORM RESPIRATORY DISORDERS
PSYCHIATRIC SYMPTOMS ASSOCIATED WITH RESPIRATORY DISEASE MEDICATIONS
FUTURE DIRECTIONS
27.6 Diabetes: Psychosocial Issues and Psychiatric Disorders
DIABETES: THE NATURE OF THE ILLNESS
PSYCHIATRIC COMORBIDITY
THE RELATIONSHIP BETWEEN DIABETES, DEPRESSION, AND OBESITY
EFFECT OF DEPRESSION AND OTHER PSYCHIATRIC AND MEDICAL COMORBIDITIES
TREATING DIABETES AND DEPRESSION
PSYCHIATRIC MEDICATIONS, OBESITY, AND TYPE 2 DIABETES
FUTURE DIRECTIONS
ACKNOWLEDGMENT
27.7 Endocrine and Metabolic Disorders
GENERAL PRINCIPLES
THYROID DISORDERS
ADRENAL DISORDERS
DIABETES MELLITUS AND INSULIN RESISTANCE
POLYCYSTIC OVARY SYNDROME
HYPERPROLACTINEMIA
27.8 Psycho-Oncology
HISTORICAL BACKGROUND
INCIDENCE OF CANCER AND CANCER MORTALITY RATES IN THE UNITED STATES
COMMON PSYCHOLOGICAL RESPONSES TO CANCER
EPIDEMIOLOGY OF PSYCHIATRIC DISORDERS IN CANCER PATIENTS
GENERAL PRINCIPLES OF ASSESSMENT AND TREATMENT IN PSYCHO-ONCOLOGY
DIAGNOSIS AND MANAGEMENT OF PSYCHIATRIC DISORDERS IN CANCER PATIENTS
PSYCHIATRIC SYNDROMES AND TUMOR SITE
PSYCHIATRIC PROBLEMS DUE TO CANCER TREATMENT
PSYCHOLOGICAL CONCERNS IN PATIENTS WITH CHRONIC CANCER
PSYCHOLOGICAL ASPECTS OF CANCER SCREENING
ETHICAL ISSUES
PSYCHOLOGICAL PROBLEMS OF FAMILIES
PSYCHOLOGICAL ISSUES FOR STAFF
CANCER IN THE PSYCHOTHERAPIST
PEDIATRIC PSYCHO-ONCOLOGY
GERIATRIC PSYCHO-ONCOLOGY
CANCER RISK AND SURVIVAL
ALTERNATIVE TREATMENTS
FUTURE DIRECTIONS
WEBSITES
27.9 End-of-Life and Palliative Care
THE CHANGING WORLD
DEATH, LIVING, AND DYING
AWARENESS OF DEATH
HUMANISM IN MEDICINE
PSYCHOLOGICAL REACTIONS OF PHYSICIANS
INSIDE THE MAELSTROM: PSYCHOLOGICAL REACTIONS OF PHYSICIANS DURING AN EPIDEMIC OR PANDEMIC
COMMUNICATION BETWEEN DOCTOR AND PATIENT
PHYSICAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH ADVANCED DISEASE
PRIMARY PSYCHOLOGICAL SYNDROMES AND SYMPTOMS IN TERMINALLY ILL PATIENTS
PSYCHOLOGICAL ACCOMPANIMENT OF THE DYING PATIENT
SPIRITUAL CONCERNS
PATIENT–FAMILY UNIT, THE FUTURE SURVIVORS
SURROGATE BURDENS AND FAMILY COPING DURING THE END OF LIFE
LEGAL ISSUES: ADVANCE DIRECTIVES, PROXIES, AND SURROGATES
CULTURAL, SPIRITUAL, AND RELIGIOUS ISSUES
STAFF–FAMILY INTERFACE
PEDIATRIC END-OF-LIFE CARE
ETHICAL RAMIFICATIONS OF THE TRIPARTITE CONNECTION
DEVELOPMENTAL STAGES
PSYCHIATRIC SYNDROMES IN THE TERMINALLY ILL CHILD
COMMUNICATION WITH ADOLESCENTS AND YOUNG ADULTS (AYA)
PSYCHOLOGICAL ISSUES OF HEALTHY SIBLINGS
STAFF DYNAMICS IN END-OF-LIFE CARE
END-OF-LIFE DECISIONS IN PEDIATRICS
WHERE WE STAND NOW
ACKNOWLEDGMENTS
27.10 Stress and Psychiatry
HISTORY
VULNERABILITY AND RESILIENCE
MEASURING STRESS PSYCHOLOGICALLY
SELECTED PHYSIOLOGIC RESPONSES TO STRESSORS
PSYCHONEUROIMMUNOLOGY
STRESS AND PSYCHIATRIC ILLNESS
PHARMACOLOGIC APPROACHES TO STRESS MANAGEMENT
COGNITIVE-BEHAVIORAL APPROACHES TO STRESS MANAGEMENT
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
27.11 Psychiatric Morbidity Following Critical Illness
PSYCHIATRIC MORBIDITY IN CRITICAL ILLNESS SURVIVORS AND THEIR FAMILY MEMBERS
COGNITIVE DYSFUNCTION IN CRITICAL ILLNESS SURVIVORS
PHYSICAL DYSFUNCTION IN CRITICAL ILLNESS SURVIVORS
INTERVENTIONS FOR PSYCHIATRIC DISORDERS IN CRITICAL ILLNESS SURVIVORS
27.12 Psychocutaneous Disorder
PSYCHOSOCIAL IMPACT OF SKIN DISORDERS
KOO CLASSIFICATION OF PSYCHOCUTANEOUS DISORDERS
ESTABLISHED PSYCHODERMATOSES
PRIMARY DERMATOLOGIC DISORDERS ASSOCIATED WITH PSYCHIATRIC SYMPTOMS
PSYCHOPHYSIOLOGIC DISORDERS
SLEEP, CIRCADIAN RHYTHMS, AND SKIN
DERMATOLOGIC SIDE EFFECTS OF PSYCHOTROPIC MEDICATIONS
FUTURE DIRECTIONS
27.13 Organ Transplantation
ORGAN TRANSPLANTATION
PSYCHIATRIC DISORDERS AFFECTING ORGAN TRANSPLANTATION
SPECIAL ISSUES IN TRANSPLANTATION
27.14 Psychiatric Care of the Burned Patient
RISK AND ASSOCIATED FACTORS FOR DEVELOPING BURN INJURIES
ALCOHOL, SUBSTANCE ABUSE, AND BURN INJURY
DELIRIUM
PAIN MANAGEMENT
BURN INJURY AND PSYCHOPATHOLOGY
PSYCHOTHERAPEUTIC INTERVENTIONS
THERAPEUTIC APPROACH TO GRIEF, REGRESSION, AND ANGER IN THE BURN PATIENT
PLASTIC SURGERY AND FACE GRAFTS
FAMILY SUPPORT
SELF-INFLICTED BURNS
CHILDREN AND BURN INJURY
STAFF SUPPORT
END OF LIFE AND ETHICS
27.15 Management of Chronic Pain
DEFINITION AND COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY AND PATHOPHYSIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
CONCLUSION
28 Additional Conditions That May Be a Focus of Clinical Attention
28.1 Malingering
DEFINITION AND COMPARATIVE NOSOLOGY
HISTORY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
CONTEXTS IN WHICH MALINGERING MAY PRESENT
CLINICAL PRESENTATIONS OF MALINGERING
CODING MALINGERING
COLLATERAL DIAGNOSTIC DATA
DIFFERENTIAL DIAGNOSES
COURSE AND PROGNOSIS
TREATMENT AND MANAGEMENT
FUTURE DIRECTIONS
28.2 Adult Antisocial Behavior, Criminality, and Violence
ORGANIZED CRIME
WHITE-COLLAR CRIME
MORALITY AND THE BRAIN
VIOLENCE
PEACE AND PEOPLE
HOMICIDE
PSYCHOPATHY
ENVIRONMENTAL INFLUENCES ON AGGRESSION
ABUSE
SOCIAL FACTORS AND VIOLENCE
BRAIN DYSFUNCTION AND VIOLENCE
SEVERE PSYCHIATRIC DISORDERS AND VIOLENCE
OFF-COLOR CRIME? VIOLENCE BY THE MEDICAL PROFESSION
ETHICAL IMPLICATIONS OF WHAT IS KNOWN ABOUT VIOLENCE
28.3 Borderline Intellectual Functioning and Academic or Educational Problem
INTELLECTUAL FUNCTIONING
BORDERLINE INTELLECTUAL AND ADAPTIVE FUNCTIONING AS A CLINICAL ENTITY OF SIGNIFICANCE
CULTURAL SENSITIVITY: A FRESH PERSPECTIVE AND AN ORIGINAL VOICE
BORDERLINE INTELLECTUAL FUNCTIONING
ACADEMIC OR EDUCATIONAL PROBLEM
FUTURE DIRECTIONS
28.4 Relational Problems
DEFINITIONS
COMPARATIVE NOSOLOGY
PARENT–CHILD RELATIONAL PROBLEM
SIBLING RELATIONAL PROBLEM
UPBRINGING AWAY FROM PARENTS
CHILD AFFECTED BY PARENTAL RELATIONSHIP DISTRESS
RELATIONSHIP DISTRESS WITH SPOUSE OR INTIMATE PARTNER
DISRUPTION OF FAMILY BY SEPARATION OR DIVORCE
HIGH EXPRESSED EMOTION LEVEL WITHIN FAMILY
UNCOMPLICATED BEREAVEMENT
CONCLUSIONS AND FUTURE RESEARCH
29 Cultural Concepts of Distress and Assessment
29.1 Cultural Concepts of Distress
HISTORICAL BACKGROUND
RELATIONSHIP TO PSYCHIATRIC CLASSIFICATION
EXAMPLES OF CULTURAL CONCEPTS OF DISTRESS
ONGOING WORK ON THE RELATIONSHIP BETWEEN CULTURAL CONCEPTS OF DISTRESS AND PSYCHIATRIC NOSOLOGY
USING CULTURAL CONCEPTS OF DISTRESS TO IMPROVE MENTAL HEALTH SERVICE DESIGN AND IMPLEMENTATION
CONCLUSION
29.2 Cultural Assessments in Psychiatry
HISTORICAL OVERVIEW
KEY DOMAINS IN PATIENT CULTURAL ASSESSMENTS
The Cultural Formulation Interview in DSM-5 and DSM-5-TR
FUTURE DIRECTIONS
30 Special Areas of Interest
30.1 Psychiatry and Reproductive Medicine
REPRODUCTIVE DEVELOPMENT
MENSTRUAL CYCLES
REPRODUCTION
SEXUALITY AND SEXUAL DYSFUNCTION
FERTILITY AND INFERTILITY
SEXUALLY TRANSMITTED INFECTIONS
PELVIC PAIN
PREMENSTRUAL MOOD SYNDROMES
PERINATAL PSYCHIATRIC DISORDERS
REPRODUCTIVE SENESCENCE
FUTURE DIRECTIONS
30.2 Genetic Counseling for Psychiatric Conditions
WHAT IS GENETIC COUNSELING?
GENETIC COUNSELING FOR PSYCHIATRIC DISORDERS
THE ROLES OF THE GENOME AND ENVIRONMENT IN MENTAL HEALTH
PRIORITIES OF PSYCHIATRIC GENETIC COUNSELING
CHALLENGES POSED BY GENOMIC TESTING FOR PSYCHIATRIC DISORDERS
ADDITIONAL ETHICAL, LEGAL, AND SOCIAL CONSIDERATIONS
ACKNOWLEDGMENTS
30.3 Physical Violence on Adults
TYPES OF ASSAULT, PREVALENCE, AND RISK FACTORS
VIOLENT CRIME
RAPE
DOMESTIC VIOLENCE AND INTIMATE PARTNER VIOLENCE
WORKPLACE VIOLENCE
SEQUELAE OF VIOLENCE AND ASSAULT
TREATMENT ISSUES
30.4 Complementary, Alternative, and Integrative Approaches in Mental Health Care
DEFINITIONS AND HISTORICAL BACKGROUND
LEGAL AND ETHICAL ISSUES
SAFETY
OVERVIEW OF CAM ASSESSMENT APPROACHES IN MENTAL HEALTH CARE
COMPLEMENTARY, ALTERNATIVE, AND INTEGRATIVE APPROACHES USED TO TREAT MENTAL ILLNESS
REVIEWS OF COMPLEMENTARY, ALTERNATIVE, AND INTEGRATIVE APPROACHES
30.5 Micronutrient Monitoring and Supplementation in Psychiatric Illness
VITAMIN D
VITAMIN B12
FOLATE (VITAMIN B9)
OMEGA-3 FATTY ACIDS
SUMMARY AND FUTURE DIRECTIONS
30.6 Disaster Psychiatry: Disasters, Terrorism, and War
ENVIRONMENTS OF CARE IN DISASTER AND MILITARY OPERATIONS
TRAUMATIC STRESS RESPONSE IN POPULATIONS AND INDIVIDUALS
ETIOLOGY AND EPIDEMIOLOGY
MANAGEMENT AND CARE DELIVERY
SPECIAL TOPICS IN DISASTER PSYCHIATRY: RESPONDING TO NATURAL, HUMAN-MADE, AND WAR EVENTS
FUTURE CHALLENGES AND EVOLVING ISSUES
CONCLUSION
ACKNOWLEDGMENT
DISCLAIMER
30.7 Psychiatry and Spirituality
FORMS AND METHODS OF ACHIEVING SPIRITUALITY
SPIRITUALITY AND RELIGION IN CLINICAL PRACTICE
30.8 Physician and Medical Student Mental Health
CURRENT FORCES IN HEALTH CARE
BURNOUT
MENTAL HEALTH CONCERNS
LIFE PHASES IN MEDICINE
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
30.9 Computers in Psychiatry
EARLY INTERNET AND COMPUTERS
IMPROVING TECHNOLOGIES
HEALTH 2.0
APPS AND ARTIFICIAL INTELLIGENCE
CONCLUSION
31 Psychiatric Emergencies
31.1 Suicide: Overview of Epidemiology, Risk and Protective Factors, Treatment, and Prevention
EPIDEMIOLOGY
RISK AND PROTECTIVE FACTORS FOR SUICIDE
PSYCHIATRIC DISORDERS AND SUICIDE
SPECIAL POPULATIONS
SUICIDE RISK ASSESSMENT
MANAGEMENT OF THE SUICIDAL PATIENT
PHARMACOTHERAPY
PSYCHOTHERAPY AND OTHER PSYCHOLOGICAL INTERVENTIONS
LOSS SURVIVORS
PUBLIC HEALTH PERSPECTIVE AND PREVENTION
31.2 Suicide Treatment
SUICIDE-RISK ASSESSMENT
THE TREATMENT OF SUICIDE
ACKNOWLEDGMENT
31.3 Other Psychiatric Emergencies
HISTORY
PRINCIPLES OF TREATMENT
PSYCHIATRIC EMERGENCIES RESULTING FROM SUBSTANCE INTOXICATION
PSYCHIATRIC EMERGENCIES RESULTING FROM SUBSTANCE WITHDRAWAL
OTHER PES-RELATED ISSUES
PSYCHOSOCIAL ISSUES IN THE PES
LEGAL ISSUES IN EMERGENCY PSYCHIATRY
CONCLUSION
32 Psychotherapies
32.1 Psychotherapy Integration
COMMON FACTORS APPROACH TO INTEGRATION
TECHNICAL ECLECTICISM
ASSIMILATIVE APPROACH TO INTEGRATION
THEORETICAL INTEGRATION
OTHER RECENT APPROACHES TO INTEGRATION: PLURALISM, STEPPED CARE, AND DIFFERENTIAL PSYCHOTHERAPEUTICS
FUTURE DIRECTIONS
32.2 Supportive Psychotherapy
RESEARCH
CLINICAL ISSUES, STRATEGIES, AND TECHNIQUES
32.3 Psychoanalysis and Psychoanalytic Psychotherapy
CORE CONCEPTS OF PSYCHOANALYTIC MODELS OF MIND
CORE CONCEPTS OF CLINICAL PROCESS
DERIVATIVES OF PSYCHOANALYSIS
CONCLUSION
ACKNOWLEDGMENT
32.4 Psychoanalytic Treatment of Anxiety, Obsessive-Compulsive and Trauma-Related Disorders
THEORETICAL ISSUES
SPECIFIC PHOBIA
PANIC DISORDER
GENERALIZED ANXIETY DISORDER
POSTTRAUMATIC STRESS DISORDER
OBSESSIVE-COMPULSIVE DISORDER
PSYCHODYNAMIC PSYCHOPHARMACOLOGY IN THE TREATMENT OF ANXIETY DISORDERS
32.5 Intensive Short-Term Psychodynamic Psychotherapies
HISTORY
CLINICAL SPECTRUM OF STDPS
EMERGING SHORT-TERM DYNAMIC PSYCHOTHERAPIES
32.6 Individual Psychodynamic Psychotherapy and Cognitive-Behavioral Therapy for Psychosis
HISTORY
THEORETICAL ISSUES
THE PSYCHOLOGY OF PSYCHOSIS
THE IMPACT OF LESS THAN OPTIMAL FAMILY RELATIONS IN SOLIDIFYING PRIMITIVE UNCONSCIOUS PHANTASY
TECHNIQUE
ETHICAL ISSUES
RESEARCH AND EVALUATION
FUTURE DIRECTIONS
CASE STUDY
32.7 Treatment of Borderline Personality Disorder
WHAT IS BPD: A REVIEW OF SYMPTOMS
WHAT YOU NEED TO KNOW ABOUT BPD: PREVALENCE, COURSE, AND COSTS TO PATIENTS AND THEIR COMMUNITIES
WHAT WORKS FOR BPD: COMMON FACTORS FROM EVIDENCE-BASED TREATMENTS COMBINED IN A GENERALIST APPROACH TO CARE
CONCLUSIONS
32.8 Behavior Therapy
HISTORY OF BEHAVIOR THERAPY
PRINCIPLES OF BEHAVIOR THERAPY
TECHNIQUES OF BEHAVIOR THERAPY
CLINICAL ISSUES
ETHICAL ISSUES
32.9 Cognitive Behavior Therapy
HISTORY
THEORETICAL ISSUES
TECHNIQUES
CLINICAL ISSUES
GOALS OF TREATMENT
ETHICAL ISSUES
RESEARCH AND EVALUATION
32.10 Interpersonal Psychotherapy
HISTORY
TIME-LIMITED INTERPERSONAL PSYCHOTHERAPY
TECHNIQUES
INTERPERSONAL PSYCHOTHERAPY DELIVERED IN A GROUP FORMAT
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
FUTURE DIRECTIONS
32.11 Dialectical Behavior Therapy
DEFINITION
HISTORY
THEORETICAL ISSUES
TECHNIQUES
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
32.12 Solution-Focused Brief Therapy
EMPIRICAL EVIDENCE
CORE SFBT SKILLS
SUMMARY
32.13 Single-Session Therapy
A BRIEF HISTORY OF SST
SINGLE-SESSION THINKING: ONE AT A TIME
THE TEMPORAL STRUCTURE OF SESSIONS AND THERAPY
KEY SINGLE-SESSION THINKING AND PRACTICE IDEAS
SOME EXAMPLES OF SST
THE ROLE OF ASSESSMENT AND RISK MANAGEMENT IN SST
SST: TOWARD THE FUTURE
CODA
ACKNOWLEDGMENTS
32.14 Mentalization-Based Treatment
DEFINITION
HISTORY
THEORETICAL ISSUES
TECHNIQUES
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
32.15 Narrative Psychiatry
WHAT IS NARRATIVE?
NARRATIVE PSYCHIATRY
FUTURE DIRECTIONS
32.16 Positive Psychology
HISTORY OF POSITIVE PSYCHOLOGY
CONCERNS OF POSITIVE PSYCHOLOGY AND CRITICISMS
EMPIRICAL FINDINGS
POSITIVE PSYCHOLOGY AND CLINICAL WORK
CONCLUSIONS
32.17 Acceptance and Commitment Therapy
FUNCTIONAL CONTEXTUALISM
RELATIONAL FRAME THEORY
EMPIRICAL EVIDENCE
PROCESSES
32.18 Hallucinogen-Assisted Psychotherapy
DEFINITION
PSYCHOPHARMACOLOGY
SUBJECTIVE EFFECTS
PROPOSED MECHANISM OF PSYCHEDELICS
HISTORY
PRINCIPLES AND GOALS OF THERAPY
CLINICAL ISSUES
CLINICAL RESEARCH
MDMA
KETAMINE
CONCLUSION
32.19 Hypnosis
HISTORY
THE TRAIT OF HYPNOTIZABILITY
HYPNOSIS AND SUGGESTIBILITY
THE DOMAIN OF HYPNOTIC EXPERIENCES AND BEHAVIOR
DIMENSIONS AND PHENOMENA OF THE HYPNOTIC EXPERIENCE
DEFINITION OF HYPNOSIS
HYPNOSIS AS REDISTRIBUTED ATTENTIVENESS
TRANCE CHARACTERISTICS
SOCIAL INFLUENCE MODELS FOR HYPNOTIC RESPONDING
THE STATE/NONSTATE CONTROVERSY
USING HYPNOTIC CHARACTERISTICS IN CLINICAL CONTEXT
NEUROBIOLOGY AND NEUROPSYCHOLOGY OF HYPNOSIS
THE ASSESSMENT OF HYPNOTIZABILITY
THE HYPNOTIC INDUCTION CEREMONY
HYPNOTHERAPY TREATMENT PLANNING AND HYPNOTHERAPY TECHNIQUES
HYPNOSIS—CLINICAL APPLICATIONS
HYPNOSIS AND PAIN
Hypnosis and Irritable Bowel Syndrome
HYPNOSIS AND ASTHMA
HYPNOSIS AND IMMUNE-RELATED DISORDERS
HYPNOSIS AND SEXUAL DYSFUNCTION
HYPNOSIS AND DERMATOLOGY
HYPNOSIS AND ADDICTIVE BEHAVIORS
HYPNOSIS IN FORENSIC PSYCHIATRY
FUTURE DIRECTIONS
ACKNOWLEDGMENT
32.20 Family and Couples Therapy
HISTORICAL TRENDS
DEFINITION
SCHOOLS OF FAMILY THERAPY
CLINICAL APPLICATIONS
COUPLES GROUP THERAPY
RESEARCH AND FUTURE DIRECTIONS
32.21 Group Psychotherapy
FOUR PHASES OF GROUP PSYCHOTHERAPY
DEFINITION
HISTORICAL ROOTS
THEORETICAL ORIENTATIONS
SELF–HELP GROUPS
THERAPEUTIC POTENTIAL OF GROUPS
SELECTION OF GROUP MEMBERS
PREGROUP PREPARATION
STAGES OF GROUP DEVELOPMENT
LEADERSHIP ISSUES
CLINICAL APPLICATIONS
RESEARCH ISSUES
FUTURE DIRECTIONS
32.22 Psychodrama, Sociodrama, Sociometry, and Sociatry
THE PSYCHODRAMATIC SYSTEM
HISTORY
METHODS, TECHNIQUES, CLINICAL ISSUES
THEORIES THAT INFORM THE METHOD
PSYCHODRAMA AS A TREATMENT OF CHOICE FOR TRAUMA
PSYCHODRAMA RESEARCH
ETHICS IN TRAINING, EDUCATION, AND PRACTICE
SOCIAL AND ORGANIC UNITY OF HUMANITY
32.23 Other Methods of Psychotherapy
CLIENT-CENTERED THERAPY
DIGNITY THERAPY
PSYCHOTHERAPY FOR THE DEAF
EXISTENTIAL PSYCHOTHERAPIES
PARADOXICAL AND STRATEGIC THERAPIES
TRANSACTIONAL PSYCHOTHERAPY
GUIDED IMAGERY THERAPY
TRANSPERSONAL PSYCHOTHERAPY
32.24 Evaluating Psychotherapy: Research Methods, Findings, and Future Directions
PSYCHOTHERAPY RESEARCH
CONSUMERS OF PSYCHOTHERAPY
EFFICACY AND EFFECTIVENESS
EFFICACY AND EFFECTIVENESS OF COMMON EVIDENCE-BASED TREATMENTS
TREATMENT VARIABLES RELATED TO OUTCOME
PATIENT VARIABLES RELATED TO OUTCOME
EMERGING THEMES AND FUTURE DIRECTIONS
33 Biologic Therapies
33.1 Preface
WHAT’S NEW IN THE BIOLOGIC THERAPIES SECTION?
33.1a General Principles of Psychopharmacology
RECEPTOR PHARMACOLOGY
INTRACELLULAR SIGNALING PATHWAYS
INTEGRATION OF NEUROTRANSMITTER SIGNALS
GENERAL ISSUES IN CLINICAL PSYCHOPHARMACOLOGY
ANTIDEPRESSANT PROPERTIES OF PSYCHEDELICS
REGULATORY ISSUES
PHARMACOLOGIC ACTIONS
DRUG FACTORS
PATIENT-RELATED FACTORS
INFORMED CONSENT AND PATIENT EDUCATION
DOSING, DURATION, AND MONITORING
TREATMENT OUTCOMES
COMBINATION OF DRUGS
SPECIAL POPULATIONS
FUTURE DIRECTIONS
33.1b Drug Development and Approval Process in the United States
SCIENTIFIC CHALLENGES IN CNS DRUG DEVELOPMENT
THE CLINICAL SCIENCE CHALLENGE: FACTORS IMPACTING SIGNAL DETECTION IN CLINICAL TRIALS
FEW USEFUL DEFINITIONS
FUTURE DIRECTIONS FOR DRUG DEVELOPMENT
MORE RELEVANT OUTCOME MEASURES
HISTORY OF DRUG REGULATION
STRUCTURE OF THE FDA
NEW DRUG DEVELOPMENT
FUTURE DIRECTIONS FOR FDA
CONCLUSION
33.1c Classification of Psychotropics: Neuroscience-Based Nomenclature (NbN)
PRINCIPLES OF THE NEUROSCIENCE-BASED NOMENCLATURE
PHARMACOLOGICALLY DRIVEN GROUPING
DOPAMINE BLOCKERS AND THE TREATMENT OF PSYCHOSIS
DOPAMINE ENHANCERS
MONOAMINE ENHANCERS AND THE TREATMENT OF DEPRESSION
CATION CHANNEL BLOCKERS, LITHIUM, AND THE TREATMENT OF BIPOLAR DISORDER
ADDITIONAL LAYERS TO NBN AND CLINICAL AIDS
CONCLUSION
33.2 Dopamine Blockers (“Antipsychotics”)
33.2a Dopamine Antagonists
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
PHARMACODYNAMICS
MECHANISM OF ACTION OF DOPAMINE RECEPTOR ANTAGONISTS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
INTERPRETATION
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
CHRONIC EXTRAPYRAMIDAL SYNDROMES
BEHAVIORAL SIDE EFFECTS
CARDIOVASCULAR EFFECTS
OTHER DOPAMINE RECEPTOR ANTAGONISTS EFFECTS
DRUG INTERACTIONS
LABORATORY INTERFERENCES
TREATMENT OF ACUTE PSYCHOSIS
MAINTENANCE TREATMENT
33.2b Dopamine-Serotonin Antagonists
Comparisons of DSAs
DOPAMINE, SEROTONIN
DOPAMINE, SEROTONIN, NOREPINEPHRINE α2
DOPAMINE, SEROTONIN, NET (NE TRANSPORTER) INHIBITOR (METABOLITE)
SEROTONIN, DOPAMINE
SEROTONIN, DOPAMINE, NOREPINEPHRINE
DOPAMINE, SEROTONIN, SEROTONIN TRANSPORTER
33.2c Dopamine Blockers and Neuromotor Adverse Effects
HISTORY
DIAGNOSTIC CRITERIA
CENTRAL NERVOUS SYSTEM CONTROL OF MOVEMENT
MEDICATION-INDUCED PARKINSONISM
NEUROLEPTIC MALIGNANT SYNDROME
MEDICATION-INDUCED ACUTE DYSTONIA
MEDICATION-INDUCED ACUTE AKATHISIA
TARDIVE DYSKINESIA
MEDICATION-INDUCED POSTURAL TREMOR
TARDIVE DYSTONIA/TARDIVE AKATHISIA
OTHER MEDICATION-INDUCED MOVEMENT DISORDER
ANTIDEPRESSANT DISCONTINUATION SYNDROME
SUMMARY
FUTURE DIRECTIONS
33.3 Dopamine Partial Agonists
33.3a Dopamine Partial Agonists
ARIPIPRAZOLE
BREXPIPRAZOLE
CARIPRAZINE
33.4 Dopamine Enhancers
33.4a Dopamine Receptor Agonists
CHEMISTRY
PHARMACOLOGIC ACTIONS
CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC IMPLICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCE
DOSAGE AND ADMINISTRATION
FUNDING AND DISCLOSURES
ACKNOWLEDGMENTS
33.4b Amphetamines, Methylphenidate, Atomoxetine, and Modafinil
ETIOLOGY AND PATHOGENESIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
MECHANISMS OF ACTION OF PSYCHOSTIMULANTS
CLINICAL PHARMACOLOGY OF PSYCHOSTIMULANTS
MODAFINIL (PROVIGIL)
ATOMOXETINE (STRATTERA)
33.5 Monoamine Enhancers (“Antidepressants”)
33.5a Reuptake Inhibitors
33.5a.1 erotonin Reuptake Inhibitors (SRIs)
OVERVIEW
THERAPEUTIC INDICATIONS
PHARMACODYNAMICS
Basis for the Delayed Onset of Therapeutic Effects of SSRIs
TOLERABILITY
CHEMISTRY AND PHARMACOKINETICS OF INDIVIDUAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS
FLUOXETINE
SERTRALINE
PAROXETINE AND PAROXETINE CR
FLUVOXAMINE AND FLUVOXAMINE CR
CITALOPRAM AND ESCITALOPRAM
DRUG INTERACTIONS
DOSING AND ADMINISTRATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND SUICIDALITY
PREGNANCY
USE IN CHILDREN
ACKNOWLEDGMENTS
33.5a.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
VENLAFAXINE AND DESVENLAFAXINE
DULOXETINE
MILNACIPRAN AND LEVOMILNACIPRAN
SUMMARY
33.5a.3 Tricyclics and Tetracyclics
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCES
DOSAGE AND ADMINISTRATION
33.5a.4 Dopamine-Noradrenaline Reuptake Inhibitors (Bupropion)
PHARMACOLOGY
CLINICAL USES
SIDE EFFECTS
DRUG INTERACTIONS
OVERDOSE
DOSING AND FORMULATIONS
33.5b 5HT1A Receptor Partial Agonists (Buspirone)
PHARMACOLOGIC ACTIONS
PHARMACOKINETICS
METABOLISM AND ELIMINATION
PHARMACODYNAMICS
CLINICAL TRIALS
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
DOSAGE AND ADMINISTRATION
33.5c Vilazodone and Vortioxetine
VILAZODONE
VORTIOXETINE
ACKNOWLEDGMENTS
33.5d Monoamine Oxidase Inhibitors
HISTORY
CHEMISTRY
MECHANISM OF ACTION
CLASSIFICATION
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
WARNINGS AND PRECAUTIONS
THERAPEUTIC INDICATIONS AND CLINICAL DRUG STUDIES
FUTURE DIRECTIONS AND INVESTIGATIONAL DRUGS
33.6 Monoamine Modulators
33.6a Trazodone
HISTORY
CHEMISTRY
PHARMACOLOGY
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCE
DOSAGE AND ADMINISTRATION
33.6b Nefazodone
CHEMISTRY
PHARMACOLOGIC ACTIONS
THERAPEUTIC INDICATIONS
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
PRECAUTIONS AND ADVERSE EFFECTS
DRUG INTERACTIONS
DOSAGE AND ADMINISTRATION
33.6c Mirtazapine
PHARMACOLOGY
INDICATIONS
OTHER INDICATIONS FOR MIRTAZAPINE
MIRTAZAPINE USE DURING PREGNANCY AND LACTATION
TOLERABILITY, SAFETY, AND TOXICITY
FUTURE DIRECTIONS
33.7 Serotonin Antagonists/Inverse Agonists
33.7a Pimavanserin
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTION
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
33.8 Noradrenaline Modulators
33.8a α2-Adrenergic Receptor Agonists: Clonidine, Clonidine Extended Release, Guanfacine, and Guanfacine Extended Release
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECT ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCE
DOSAGE AND ADMINISTRATION
33.8b β-Adrenergic Receptor Antagonists
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
PHARMACODYNAMICS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
TERATOGENIC EFFECTS
THERAPEUTIC INDICATIONS
DOSAGE AND ADMINISTRATION
33.9 GABA Enhancers
33.9a Barbiturates and Similarly Acting Substances
CHEMISTRY
PHARMACOLOGIC ACTIONS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCES
DOSAGE AND ADMINISTRATION
NONBARBITURATE, NONBENZODIAZEPINE SEDATIVE-HYPNOTIC AGENTS
OTHER SEDATIVE-HYPNOTICS
33.9b Benzodiazepine Receptor Agonists and Antagonists
GABA–BENZODIAZEPINE RECEPTOR COMPLEX
BENZODIAZEPINE RECEPTOR LIGANDS
BENZODIAZEPINES
NONBENZODIAZEPINE AGONISTS OF THE BENZODIAZEPINE RECEPTOR
BREXANOLONE
NONPRESCRIPTION, DESIGNER AND OTHER ILLICIT BENZODIAZEPINES
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
USE IN PREGNANCY
BENZODIAZEPINES IN THE ELDERLY
PRECAUTIONS AND ADVERSE EFFECTS
DRUG INTERACTIONS AND LABORATORY INTERFERENCES
DOSAGE AND ADMINISTRATION
BENZODIAZEPINE RECEPTOR ANTAGONISTS
INVESTIGATIONAL DRUGS
33.10 Cation Function Modulators and Lithium (“Mood Stabilizers”)
33.10a Calcium Channel Inhibitors
CALCIUM CHANNELS
CHEMISTRY
PHARMACOLOGIC ACTIONS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DOSAGE AND ADMINISTRATION
INVESTIGATIONAL DRUGS AND PREDICTION OF RESPONSE
33.10b Gabapentin, Topiramate, Tiagabine, Levetiracetam, Zonisamide, and Pregabalin
GABAPENTIN
TOPIRAMATE
TIAGABINE
LEVETIRACETAM
ZONISAMIDE
PREGABALIN
PERAMPANEL
33.10c Carbamazepine
CHEMISTRY
PHARMACOLOGIC ACTIONS
PHARMACODYNAMICS
CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
33.10d Lamotrigine
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCES
DOSAGE AND ADMINISTRATION
33.10e Valproate
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
CLINICAL DRUG STUDIES
THERAPEUTIC INDICATIONS
PRECAUTIONS
DRUG INTERACTIONS
VALPROATE AND LABORATORY INTERFERENCE
DOSAGE AND ADMINISTRATION
33.10f Lithium
CHEMISTRY
PHARMACOKINETICS AND PHARMACODYNAMICS
THERAPEUTIC INDICATIONS
POLYPHARMACY AND ADMINISTRATION OF LITHIUM
THE IMPORTANCE OF PATIENT HISTORY
EFFECTS OF LITHIUM IN NORMALS
MECHANISMS OF ACTION INCLUDING ANIMAL MODELS
SUICIDALITY
LITHIUM IN PREGNANCY, CHILDBIRTH, AND LACTATION
CHILDHOOD USE
GERIATRIC USE
LITHIUM IN CLUSTER HEADACHE AND ALZHEIMER’S
LITHIUM IN AMPHETAMINE, METHYLPHENIDATE, OR COCAINE ABUSE
INDIVIDUAL DIFFERENCES AND PREDICTION OF LITHIUM RESPONSE IN BIPOLAR DISORDER
TOXICITY
SIDE EFFECTS
LITHIUM IN SCHIZOAFFECTIVE DISORDER
LITHIUM AND AGGRESSIVITY
LITHIUM AUGMENTATION OF ACUTE ANTIDEPRESSANT TREATMENT
LITHIUM IN UNIPOLAR DEPRESSION MAINTENANCE THERAPY
IS LITHIUM IN ANY SENSE SPECIFIC?
SUMMARY
ACKNOWLEDGMENT
33.11 Acetylcholine Blockers and Enhancers
33.11a Anticholinergics and Amantadine
HISTORY
ATROPINE
ANTICHOLINERGIC AGENTS
SCOPOLAMINE
AMANTADINE
33.11b Cholinesterase Inhibitors and Memantine
TACRINE
DONEPEZIL
RIVASTIGMINE
GALANTAMINE
MEMANTINE
FUTURE DIRECTIONS
33.12 Histamine Modulators
33.12a Histamine Blockers and Enhancers
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
METABOLISM
ELIMINATION
PHARMACODYNAMICS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
COMMONLY USED HISTAMINERGIC AGENTS IN PSYCHIATRY
OTHER THERAPEUTIC INDICATIONS IN PSYCHIATRY
FUTURE DIRECTIONS
PRECAUTIONS AND ADVERSE EVENTS
DRUG INTERACTIONS
LABORATORY INTERFERENCES
DOSAGE ADMINISTRATION
33.13 Pharmacological Treatments of Substance Abuse
33.13a Opioid Receptor Modulators
33.13a.1 Opioid Maintenance Treatments: Methadone and Buprenorphine
PHYSICAL DEPENDENCE AND WITHDRAWAL
OPIOID AGONIST THERAPIES FOR OPIOID USE DISORDER
METHADONE
BUPRENORPHINE
OPIOID AGONISTS IN THE TREATMENT OF PAIN IN INDIVIDUALS WITH ADDICTIVE DISORDERS
FUTURE DIRECTIONS
33.13a.2 Opioid Receptor Antagonists: Naltrexone and Nalmefene
INTRODUCTION AND HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
DESIGN AND INTERPRETATION OF CLINICAL DRUG STUDIES
THERAPEUTIC INDICATIONS
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCES
DOSAGE AND ADMINISTRATION
INVESTIGATIONAL DRUGS
33.13b Disulfiram and Acamprosate
DISULFIRAM
ACAMPROSATE
ACKNOWLEDGMENTS
33.14 Fast-Acting Pharmacologic Treatments
33.14a Esketamine and Ketamine
HISTORY
CHEMISTRY
PHARMACOLOGIC ACTIONS
CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
DRUG INTERACTIONS
DOSAGE AND ADMINISTRATION
FUNDING AND DISCLOSURES
ACKNOWLEDGMENTS
33.14b MDMA, Psilocybin, Ayahuasca, and Ibogaine
BACKGROUND AND EARLY STUDIES PREBANNING
THE TWENTY-FIRST–CENTURY RESURRECTION OF PSYCHEDELICS AND MDMA IN PSYCHIATRY
PSILOCYBIN TRIALS
DMT AND AYAHUASCA
IBOGAINE
METHYLENEDIOXYMETHAMPHETAMINE
HOW DO THESE DRUGS WORK?
MICRODOSING
33.15 Hormone Receptor Enhancers
33.15a Melatonin Receptor Agonists
CHEMISTRY
PHARMACOLOGIC ACTIONS
CLINICAL DRUG STUDIES
EFFECTS ON SPECIFIC ORGANS AND SYSTEMS
THERAPEUTIC INDICATIONS
PRECAUTIONS AND ADVERSE REACTIONS
DRUG INTERACTIONS
LABORATORY INTERFERENCE
DOSAGE AND ADMINISTRATION
INVESTIGATIONAL DRUGS
33.15b Thyroid Hormones
USE OF THYROID HORMONES IN TREATMENT
THYROID HORMONE BIOCHEMISTRY
PHARMACOLOGIC ACTION
THYROID FUNCTION IN PRIMARY AFFECTIVE DISORDERS
AFFECTIVE DISORDERS IN PRIMARY THYROID DISORDERS
CLINICAL HORMONE STUDIES
33.16 Combination Pharmacotherapy
COMBINATION STRATEGIES IN THE TREATMENT OF MAJOR DEPRESSION
COMBINATION PHARMACOTHERAPY IN BIPOLAR DISORDER
COMBINATION STRATEGIES IN THE TREATMENT OF SCHIZOPHRENIA
FUTURE DIRECTIONS
33.17 Sex and Psychopharmacology
33.17a Sex Differences in Psychopharmacology
SEX DIFFERENCES IN PHARMACOKINETICS AND PHARMACODYNAMICS
GONADAL STEROID MODULATION
REPRODUCTIVE PERIODS THAT AFFECT PHARMACOKINETICS AND PHARMACODYNAMICS
SEX DIFFERENCES IN THE PHARMACOKINETICS OF SPECIFIC DRUG CLASSES
EFFICACY AND SAFETY
CONCLUSION
33.17b Reproductive Hormonal Therapy: Theory and Practice
STRUCTURE AND ACTIONS
WHY REPRODUCTIVE HORMONAL THERAPY?
TYPES OF REPRODUCTIVE HORMONE THERAPY IN AFFECTIVE ILLNESS
FUTURE DIRECTIONS
33.17c Pharmacologic Treatment of Sexual Dysfunction
PATHOPHYSIOLOGY
ASSESSMENT
TREATMENT
PSYCHOTROPIC-INDUCED SEXUAL DYSFUNCTION AND ITS MANAGEMENT
RECOMMENDATIONS
33.18 Psychopharmacology Across the Life Cycle
33.18a Pediatric Psychopharmacology
ROLE OF PHARMACOTHERAPY IN CHILDREN AND ADOLESCENTS
PEDIATRIC ANXIETY AND DEPRESSIVE DISORDERS
PHARMACOTHERAPIES FOR BIPOLAR DISORDER AND SCHIZOPHRENIA IN YOUTH
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
CONSIDERATIONS FOR EFFECTIVE PHARMACOTHERAPY IN CHILDREN AND ADOLESCENTS
33.18b Biologic Therapies: Geriatric Psychopharmacology
33.19 Biologic Therapies Around the Globe
33.19a Essential List of Medicines
THE ESSENTIAL LIST OF MEDICINES
33.19b Biologic Therapies in Africa
OVERVIEW OF THE EFFICACY AND SIDE EFFECTS OF BIOLOGIC THERAPIES IN AFRICA
SPECIFIC EXAMPLES OF PSYCHOTROPIC MEDICATIONS
ELECTROCONVULSIVE THERAPY
TRANSCRANIAL MAGNETIC RESONANCE STIMULATION
ATTITUDES OF PATIENTS AND CLINICIANS TO PHYSICAL THERAPIES
PHARMACOECONOMICS
33.19c Biologic Therapies in India
33.19d Biologic Therapies in Latin America
PREVALENCE AND GAP IN TREATMENT OF MENTAL DISORDERS
PARTICULARITIES IN DRUG TREATMENT AND DRUG RESPONSE
OTHER BIOLOGIC THERAPIES
33.20 Brain Stimulation
33.20a Electroconvulsive Therapy
HISTORICAL OVERVIEW
ELECTRICAL INDUCTION OF SEIZURES
MECHANISMS OF ACTION
INDICATIONS
PATIENT MANAGEMENT
INTERACTIONS OF MEDICATIONS AND ECT
PHYSIOLOGY, ADVERSE EFFECTS, AND CONTRAINDICATIONS TO ECT
FUTURE DIRECTIONS
33.20b Brain Stimulation Methods
THERAPEUTIC NEUROMODULATION: TREATING PSYCHIATRIC DISORDERS THROUGH BRAIN STIMULATION
PSYCHIATRIC APPLICATIONS OF BRAIN STIMULATION
BRAIN STIMULATION TOOLS
ACKNOWLEDGMENT
33.20c Neurosurgical Treatments
HISTORY
PATIENT SELECTION
PREOPERATIVE WORKUP
POSTOPERATIVE CARE
DESIGN AND INTERPRETATION OF CLINICAL STUDIES
LESION PROCEDURES
DEEP BRAIN STIMULATION
CURRENT STATE OF PSYCHIATRIC NEUROSURGERY
RESEARCH AND FUTURE DIRECTIONS
34 Child Psychiatry
34.1 Introduction and Overview
UPDATES IN CHILD AND ADOLESCENT PSYCHIATRY
CLASSIFICATION OF CHILDHOOD PSYCHIATRIC DISORDERS AND HIGHLIGHTS OF MODIFICATIONS IN DSM-5-TR AND DISORDERS UNDER CONSIDERATION
DEVELOPMENTAL PERSPECTIVE: IDENTIFYING THE EMERGENCE OF A CHILDHOOD PSYCHIATRIC DISORDER
GENE X ENVIRONMENT INTERACTIONS: RISK AND PROTECTIVE FACTORS
INTERVENTIONS FOR PSYCHIATRIC DISORDERS IN YOUTH
34.2 Child Development
BRAIN DEVELOPMENT
LANGUAGE DEVELOPMENT
COGNITIVE DEVELOPMENT
SOCIAL DEVELOPMENT
EMOTIONAL DEVELOPMENT
MOTOR DEVELOPMENT
SENSORY DEVELOPMENT
GENDER IDENTITY
RACIAL AND ETHNIC IDENTITY DEVELOPMENT
PSYCHOSEXUAL DEVELOPMENT
CONCLUSION
ACKNOWLEDGMENTS
34.3 Adolescent Development
DEFINITION
WHAT IS TYPICAL IN ADOLESCENCE?
CULTURAL CONSIDERATIONS
STAGES OF ADOLESCENCE
COMPONENTS OF ADOLESCENCE
ADOLESCENT BRAIN DEVELOPMENT: CORRELATIONS WITH EMOTIONAL, SOCIAL, AND COGNITIVE CHANGES
CURRENT ENVIRONMENTAL INFLUENCES AND ADOLESCENCE
35 Child Psychiatric Examination
35.1 Psychiatric Examination of the Infant, Child, and Adolescent
CLINICAL INTERVIEW OF THE CHILD
SPECIAL ISSUES IN THE ASSESSMENT OF ADOLESCENTS
ASSESSMENT OF INFANTS AND TODDLERS
SPECIAL TYPES OF ASSESSMENT
STANDARDIZED ASSESSMENT INSTRUMENTS FOR CHILDREN AND ADOLESCENTS
PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL ASSESSMENT
PEDIATRIC AND OTHER ADJUNCTIVE EVALUATIONS
DIAGNOSTIC FORMULATION AND RECOMMENDATIONS
35.2 Psychiatric Assessment of Preschool Children
DEVELOPMENTALLY APPROPRIATE CRITERIA FOR PSYCHIATRIC SYMPTOMS AND DISORDERS IN PRESCHOOL CHILDREN
COMPREHENSIVE, EVIDENCE-BASED PSYCHIATRIC ASSESSMENTS OF PRESCHOOL CHILDREN
CLINICAL FORMULATION AND TREATMENT PLANNING
35.3 Neuropsychological and Psychoeducational Assessment of Children
BASICS OF COGNITIVE ASSESSMENT
PSYCHOEDUCATIONAL AND NEUROPSYCHOLOGICAL ASSESSMENT
COGNITIVE DOMAINS OF ASSESSMENT
NEUROPSYCHOLOGICAL CONCLUSIONS
DIFFERENT APPROACHES
35.4 Psychiatric Emergencies in Children and Adolescents
EPIDEMIOLOGY
PRIORITIES OF EMERGENCY PSYCHIATRIC EVALUATION FOR CHILDREN AND ADOLESCENTS
PRINCIPLES OF EMERGENCY PSYCHIATRIC CARE FOR CHILDREN AND ADOLESCENTS
SPECIFIC PSYCHIATRIC EMERGENCIES IN CHILDREN AND ADOLESCENTS
LEGAL CONSIDERATIONS AND CONFIDENTIALITY
MODELS OF CARE AND INNOVATIONS
CONCLUSION
36 Genetics in Child Psychiatry
THE GENETIC BASIS OF PSYCHIATRIC DISEASE
PHARMACOGENOMICS IN CHILD PSYCHIATRY
CLINICAL CORRELATIONS
LIMITATIONS OF CURRENT RESEARCH
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
37 Neuroimaging in Psychiatric Disorders of Childhood
TECHNIQUES AND PRACTICAL CONSIDERATIONS
NORMAL DEVELOPMENT
SPECIFIC NEUROPSYCHIATRIC DISORDERS
FUTURE DIRECTIONS
38 Temperament: Risk and Protective Factors for Child Psychiatric Disorders
HISTORICAL ANTECEDENTS
DEFINITION OF TEMPERAMENT
MAJOR DIMENSIONS
FEATURES OF TEMPERAMENT
NEUROBIOLOGY AND ETIOLOGY
TEMPERAMENT AND PSYCHOPATHOLOGY
OTHER CONCEPTS IN TEMPERAMENT–PSYCHOPATHOLOGY RELATIONS
CLINICAL IMPLICATIONS
39 Intellectual Disability
HISTORICAL OVERVIEW
DEFINITION OF INTELLECTUAL DISABILITY
PREVALENCE
GENETIC INTELLECTUAL DISABILITY SYNDROMES AND BEHAVIORAL PHENOTYPES
DEVELOPMENTAL CONSIDERATIONS IN CHILDREN WITH INTELLECTUAL DISABILITY
TREATMENT
TREATMENT OF MENTAL DISORDERS
40 Specific Learning Disorder
SIGNIFICANCE OF SLD FOR PSYCHIATRISTS
DEFINITION
HISTORY AND COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
CLINICAL FEATURES, ASSOCIATED PROBLEMS, AND DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
41 Developmental Coordination Disorder
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
CLINICAL FEATURES OF DCD
COURSE AND PROGNOSIS
TREATMENT
42 Communication
42.1 Language Disorder
DEFINITION AND COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
ACKNOWLEDGMENTS
42.2 Social (Pragmatic) Communication Disorder
HISTORY
DIAGNOSTIC FEATURES
DIFFERENTIAL DIAGNOSIS
ETIOLOGY
EPIDEMIOLOGY
DEVELOPMENT AND COURSE
TREATMENT
SUMMARY
42.3 Speech Sound Disorder
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
ACKNOWLEDGMENTS
42.4 Stuttering
HISTORY AND COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
ACKNOWLEDGMENTS
42.5 Unspecified Communication Disorder
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
43 Autism Spectrum Disorders
OVERVIEW
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
POSTMORTEM AND NEUROIMAGING STUDIES
NEUROCHEMISTRY
IMMUNE THEORIES OF ASD
DIAGNOSIS AND CLINICAL FEATURES
PHYSICAL CHARACTERISTICS
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
44 Attention-Deficit Disorders
44.1 Attention-Deficit/Hyperactivity Disorder
HISTORY
DIAGNOSIS AND DEFINITION
COMPARATIVE NOSOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
MEDICAL AND LABORATORY EXAMINATION
RATING SCALES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT OF ADHD
SUMMARY AND CONCLUSIONS
SPECIFIC CASE OF CHILDHOOD ADHD
ACKNOWLEDGMENTS
44.2 Adult Manifestations of Attention-Deficit/Hyperactivity Disorder
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
COURSE AND PROGNOSIS
TREATMENT
FUTURE DIRECTIONS
45 Disruptive Behavior Disorders in Children and Adolescents
OPPOSITIONAL DEFIANT DISORDER
CONDUCT DISORDER
FUTURE DIRECTIONS
46 Feeding and Eating Disorders of Infancy and Early Childhood
DEFINITION
HISTORY AND COMPARATIVE NOSOLOGY
SPECIFIC FEEDING DISORDER SUBTYPES
47 Tic Disorders
DEFINITIONS
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY AND PATHOPHYSIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
SUMMARY AND FUTURE DIRECTIONS
48 Elimination Disorders
ENURESIS
ENCOPRESIS
49 Other Disorders of Infancy, Childhood, and Adolescence
49.1 Reactive Attachment Disorder and Disinhibited Social Engagement Disorder
ATTACHMENT THEORY
IMPACT OF EARLY ENVIRONMENT
EVOLVING NOSOLOGY
ETIOLOGY
EPIDEMIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
CONCLUDING THOUGHTS
49.2 Stereotypic Movement Disorders in Children
HISTORY
ETIOLOGY
EPIDEMIOLOGY
NOSOLOGY
DIFFERENTIAL DIAGNOSIS
ICD-10 AND 11
DIAGNOSIS
INJURIOUS BEHAVIORS
TREATMENT
50 Mood Disorders in Children and Adolescents
50.1 Depressive Disorders and Suicide
DEFINITION
HISTORY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
LABORATORY EXAMINATIONS/ASSESSMENT INSTRUMENT
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
PHARMACOLOGIC TREATMENT
PSYCHOTHERAPY
TREATMENT-RESISTANT DEPRESSION
OTHER TREATMENT COMPONENTS
SUICIDAL BEHAVIOR IN CHILDREN AND ADOLESCENTS
50.2 Early-Onset Bipolar Disorder
HISTORY
EPIDEMIOLOGY
ETIOLOGY, MECHANISMS, AND RISK FACTORS
BRAIN STRUCTURE AND FUNCTION
ASSESSMENT
DIFFERENTIAL DIAGNOSIS
COURSE
TREATMENT
FUTURE DIRECTIONS
51 Anxiety Disorders in Children
51.1 Obsessive-Compulsive Disorder in Childhood
DEFINITIONS
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
51.2 Posttraumatic Stress Disorder in Children and Adolescents
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
FUTURE DIRECTIONS
51.3 Separation Anxiety, Generalized Anxiety, and Social Anxiety
SEPARATION ANXIETY DISORDER
SOCIAL ANXIETY DISORDER
GENERALIZED ANXIETY DISORDER
TREATMENT OF ANXIETY DISORDERS
FUTURE DIRECTIONS
51.4 Selective Mutism
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
52 Early-Onset Psychotic Disorders
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
FUTURE DIRECTIONS
53 Child Psychiatry: Psychiatric Treatment
53.1 Psychodynamic Psychotherapy (Child Psychiatry)
HISTORY
THEORETICAL ISSUES IN PSYCHODYNAMIC WORK WITH CHILDREN
PRACTICAL MATTERS
CLINICAL CONSIDERATIONS
AN OVERVIEW OF THE PHASES OF TREATMENT
RESEARCH AND EVALUATION
FUTURE DIRECTIONS
53.2 Cognitive-Behavioral Psychotherapy for Children and Adolescents
HISTORY
THEORETICAL ISSUES
TECHNIQUES
CLINICAL ISSUES
CASE EXAMPLES
GOALS OF TREATMENT
ETHICAL ISSUES
RESEARCH AND EVALUATION
53.3 Group Psychotherapy
HISTORY
THEORETICAL ISSUES
TECHNIQUES
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
53.4 Family Therapy
PROCESS OF FAMILY THERAPY
PROMOTING EFFECTIVE AND REWARDING PARENTING
FAMILY THERAPY FOR SPECIFIC PROBLEMS
FUTURE DIRECTIONS
53.5 Pediatric Psychopharmacology
DEVELOPMENTAL PHARMACOLOGY
ROLE OF PHARMACOTHERAPY IN CHILDREN AND ADOLESCENTS
ANXIETY DISORDERS
PHARMACOTHERAPY FOR MAJOR DEPRESSIVE DISORDER
PHARMACOTHERAPIES FOR BIPOLAR DISORDER
OBSESSIVE-COMPULSIVE DISORDER (OCD)
POSTTRAUMATIC STRESS DISORDER
SCHIZOPHRENIA
EXTERNALIZING DISORDERS
AUTISM SPECTRUM DISORDERS (ASD)
SLEEP-RELATED DISORDERS
Tic DISORDERS
CONCLUSIONS
53.6 Inpatient Psychiatric, Partial Hospitalization, and Residential Treatment for Children and Adolescents
REASONS FOR HOSPITALIZATION AND TYPICAL REFERRAL SOURCES
LEVELS OF CARE
CHALLENGES RELATED TO THE COVID-19 PANDEMIC
GLOBAL PERSPECTIVE
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
53.7 Community-Based Treatment
HISTORY
THEORETICAL ISSUES
TECHNIQUES
ROLES AND FUNCTIONS OF PSYCHIATRISTS
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
FUTURE RESEARCH NEEDS
53.8 The Treatment of Adolescents
CONTROVERSIES IN CONCEPTUALIZING NORMALITY AND PATHOLOGY IN ADOLESCENCE
WHEN DOES AN ADOLESCENT REQUIRE TREATMENT?
MODALITY OF PSYCHIATRIC TREATMENT
RESILIENCE AND WELL-BEING
EFFECTIVE ADOLESCENT THERAPY
FUTURE DIRECTIONS
54 Child Psychiatry: Special Areas of Interest
54.1 Adoption and Foster Care
FOSTER CARE
ADOPTION
54.2 Child Maltreatment
DEFINITIONS
HISTORY OF CHILD MALTREATMENT
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
RISK FACTORS
DIAGNOSIS AND CLINICAL FEATURES
EVALUATION PROCESS
PHYSICAL EXAMINATION OF SUSPECTED CHILD MALTREATMENT
SPECIAL TESTS AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
SPECIAL ISSUES
REPORTING LAWS AND PRACTICES
TREATMENT
PREVENTION
FUTURE DIRECTIONS
54.3 Children’s Reaction to Illness and Hospitalization
HISTORY
CONTEMPORARY PEDIATRIC HOSPITALS
COLLABORATIVE CARE, INTEGRATED CARE, AND THE MEDICAL HOME
IMPACT OF ILLNESS AND HOSPITALIZATION ON CHILDREN
IMPACT OF CHILD’S ILLNESS ON FAMILIES
A CHILD’S RESPONSE TO ILLNESS AND HOSPITALIZATION AT DIFFERENT AGES
RESPONSE TO SPECIFIC ILLNESSES
TRANSITION FROM PEDIATRIC TO ADULT MEDICAL CARE
SOCIAL MEDIA
54.4 Psychiatric Sequel of HIV and AIDS
EPIDEMIOLOGY
ETIOLOGY
CLINICAL FEATURES
TREATMENT
CONCLUSION
54.5 Adolescent Substance Use Disorders
PREVALENCE OF SUBSTANCE USE
CLINICAL EVALUATION
SUMMARY, DISCUSSION, AND CONCLUSION
54.6 Forensic Child and Adolescent Psychiatry
GUIDELINES
TREATING CLINICIANS TAKING ON A FORENSIC ROLE
FORENSIC EVALUATIONS
CUSTODY ISSUES
CIVIL LITIGATION
JUVENILE JUSTICE CASES
TELEHEALTH FORENSIC EVALUATIONS
FUTURE DIRECTIONS
ACKNOWLEDGMENT
54.7 Ethical Issues in Child and Adolescent Psychiatry
CODES OF MEDICAL ETHICS—NATIONAL AND INTERNATIONAL
MEDICINE AND MENTAL DISTURBANCE
CHILDREN AND ETHICAL CONSIDERATIONS
CHILD-RELATED CONCERNS
EFFECTS OF CULTURE AND RELIGION
PROVISION OF CARE
CURRENT AND FUTURE ISSUES
TEACHING ETHICS AND REPORTING VIOLATIONS
54.8 School Consultation and Collaborating With the Educational System
EDUCATIONAL OUTCOMES AND MENTAL HEALTH
SCHOOL SYSTEMS
SCHOOL RESOURCES AND PROGRAMMING
ROLE OF PSYCHIATRISTS IN SCHOOLS
ACKNOWLEDGMENTS
54.9 Prevention of Psychiatric Disorders in Children and Adolescents
DEFINITIONS
EXAMPLES OF RESEARCH ON THE PREVENTION OF MENTAL HEALTH PROBLEMS IN YOUTH
COMMUNITY-LEVEL PREVENTIVE INTERVENTIONS FOR CHILD MALTREATMENT
ISSUES IN THE PREVENTION OF MENTAL ILLNESS
LOOKING FORWARD TO THE FUTURE
ACKNOWLEDGMENTS
54.10 Child Mental Health Services Research
HISTORICAL CONTEXT
ACCESS TO CARE
QUALITY OF CARE
AREAS FOR FUTURE RESEARCH
54.11 Impact of Terrorism and School Shootings on Children
DEFINITION OF TERRORISM
CHILDHOOD REACTIONS TO TERRORISM-INDUCED TRAUMA
RISK AND PROTECTIVE FACTORS FOR CHILDREN EXPOSED TO TERRORISM
CHILDREN’S RESPONSES TO MEDIA EXPOSURE TO TERRORIST EVENTS AND SCHOOL SHOOTINGS
LITERATURE REVIEW OF TERRORIST EVENTS
CLINICAL INTERVENTIONS AND TREATMENT
FUTURE DIRECTIONS
54.12 Impact on Parents of Raising a Child with Psychiatric Illness and/or Developmental Disability
IMPACT ON PARENTS OF RAISING A CHILD WITH AN AUTISM SPECTRUM DISORDER
IMPACT ON PARENTS OF RAISING A CHILD WITH BIPOLAR DISORDER
IMPACT ON PARENTS OF RAISING A CHILD WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
IMPACT ON FAMILIES OF RAISING A CHILD DIAGNOSED WITH SCHIZOPHRENIA
SUMMARY
54.13 Pediatric Sleep Disorders
SLEEP EVALUATION METHODS
NEUROCOGNITIVE EFFECTS OF SLEEP DISRUPTION
SLEEP DISORDERS IN CHILDREN
54.14 Internet Gaming Disorder in Youth
PREVALENCE
DIAGNOSTIC CRITERIA: GAMING DISORDER (ICD-11) AND INTERNET GAMING DISORDER (DSM-5 CONDITION FOR FURTHER STUDY)
BENEFITS AND RISKS OF ONLINE VIDEO GAME PLAY IN YOUTH
BIOLOGIC CORRELATES OF INTERNET GAMING DISORDER
COMORBIDITY
TREATMENT OF INTERNET GAMING DISORDER
CLINICAL CONSIDERATIONS
FUTURE DIRECTIONS
54.15 Social Media and Youth
BENEFITS OF SOCIAL MEDIA USE FOR YOUTH
RISKS OF SOCIAL MEDIA USE FOR YOUTH
RISKS OF INTENSIVE SOCIAL MEDIA USE IN YOUTH
CLINICAL CONSIDERATIONS
CONCLUSIONS
RESOURCES FOR FAMILIES
54.16 Gay, Bisexual, Transgender, Queer/Questioning, Intersex, and Asexual (LGBTQIA) Youth
SEXUAL ORIENTATION
SEX AND GENDER
YOUTH TRAUMA AND RESILIENCE
CLINICAL APPROACHES FOR LGBTQIA YOUTH AND THEIR FAMILIES
ACKNOWLEDGMENT
54.17 Racism and Discrimination’s Impact on the Health and Well-Being of Developing Children and Adolescents
DEFINING TERMINOLOGY
CONTEXTUALIZING RACE-BASED TRAUMATIC STRESS AS AN ADVERSE CHILDHOOD EXPERIENCE
EMERGING RESEARCH/NEUROBIOLOGY/NEUROPLASTICITY
STRESS, CORTISOL LEVELS, HYPOTHALAMIC–PITUITARY–ADRENAL AXIS
IMPACT OF RACISM AND DISCRIMINATION ON DEVELOPMENT
RACISM IN SYSTEMS OF CARE
RACIAL INEQUITIES IN MENTAL HEALTH TREATMENT AND OUTCOMES
THE ROLE OF THE CHILD AND ADOLESCENT PSYCHIATRIST
54.18 Forensic Evaluations of Child and Adolescent Migrants
MENTAL HEALTH PREVALENCE IN ASYLUM-SEEKING POPULATIONS
OVERVIEW OF THE EVALUATION PROCESS
GENERAL TIPS FOR WRITING AN EFFECTIVE PSYCHOLOGICAL AFFIDAVIT FOR ASYLUM SEEKERS
CONCLUSION
55 Geriatric Psychiatry
55.1 Overview
55.1a Introduction to Geriatric Psychiatry
WHAT IS NORMAL AGING?
DEMOGRAPHICS OF OLDER PEOPLE WITH MENTAL ILLNESSES
GERIATRIC PSYCHIATRY AS A SUBSPECIALTY
COMMON MENTAL ILLNESSES IN OLDER PEOPLE
POSITIVE SIDE OF AGING
SUCCESSFUL COGNITIVE AND EMOTIONAL AGING
IMPLICATIONS FOR FUTURE PROGRESS
55.2 Assessment
55.2a Psychiatric Assessment of the Older Patient
HISTORY TAKING
MEDICAL EXAMINATION
DAILY FUNCTIONING
NEUROLOGIC EVALUATION
RATING SCALES
BIOMARKERS FOR A DEMENTIA DIAGNOSIS
COMPETENCE
SYNDROMES SPECIFIC TO GERIATRIC PATIENTS
SUMMARY
55.2b Complementary and Integrative Geriatric Psychiatry
THE EPIDEMIOLOGY OF COMPLEMENTARY AND INTEGRATIVE MEDICINE USE
PERSPECTIVES ON THE DIGITIZATION OF SUITABLE THERAPIES
FUTURE DIRECTIONS
CONCLUSION
55.2c The Aging Brain
CONCEPTS AND CHALLENGES IN STUDYING BRAIN AGING
MECHANISMS IMPLICATED IN BRAIN AGING
STRUCTURAL CHANGES ASSOCIATED WITH BRAIN AGING
LESIONS IN THE AGING BRAIN
NEUROCHEMICAL CHANGES IN AGING
CHANGES IN COGNITIVE AND MOTOR ABILITIES ASSOCIATED WITH AGING
AGE-ASSOCIATED BRAIN DISEASES
BRAIN AGING IN THE OLDEST-OLD AND CENTENARIANS
PROSPECTS FOR HEALTHY BRAIN AGING
ACKNOWLEDGMENTS
55.2d Psychological Changes With Normal Aging
DESIGN AND SAMPLING ISSUES
MENTAL HEALTH AND PERSONALITY
ADJUSTMENT AND COPING IN OLDER ADULTS
SOCIAL FUNCTIONING IN LATE LIFE
COGNITIVE AGING
SUCCESSFUL AGING
IMPLICATIONS FOR CLINICAL PRACTICE
55.2e Neuropsychological Evaluation
WHAT IS A NEUROPSYCHOLOGIST?
WHAT IS A NEUROPSYCHOLOGICAL EVALUATION?
HISTORICAL DEVELOPMENT
COMMON USES OF NEUROPSYCHOLOGICAL EVALUATIONS
ASSESSMENT DOMAINS AND COMMONLY USED MEASURES
OTHER ASPECTS OF COMPREHENSIVE NEUROPSYCHOLOGICAL EVALUATION
ISSUES IN THE ASSESSMENT OF OLDER ADULTS
55.2f Genetics of Late-Life Neurodegenerative Disorders
GENETIC METHODS AND PRINCIPLES
MAJOR OR MILD NEUROCOGNITIVE DISORDER DUE TO ALZHEIMER’S DISEASE
MAJOR OR MILD NEUROCOGNITIVE DISORDER DUE TO PARKINSON DISEASE
MAJOR OR MILD NEUROCOGNITIVE DISORDER WITH LEWY BODIES (DEMENTIA WITH LEWY BODIES)
MAJOR OR MILD FRONTOTEMPORAL NEUROCOGNITIVE DISORDER (PICK DISEASE AND OTHER FRONTOTEMPORAL DEMENTIAS)
MAJOR OR MILD VASCULAR NEUROCOGNITIVE DISORDER (VASCULAR DEMENTIA)
MAJOR OR MILD NEUROCOGNITIVE DISORDER DUE TO PRION DISEASE (CREUTZFELDT–JAKOB DISEASE AND OTHER TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES)
FUTURE CLINICAL DIRECTIONS
FUTURE RESEARCH DIRECTIONS
CLINICAL IMPLICATIONS
55.3 Psychiatric Disorders of Late Life
55.3a Assessment of Functioning
WHAT IS EVERYDAY FUNCTIONING?
DOMAINS OF EVERYDAY FUNCTIONING ASSESSMENT
FACTORS INFLUENCING EVERYDAY FUNCTIONING
ASSESSMENT OF EVERYDAY FUNCTIONING
CLINICAL POPULATIONS AND EVERYDAY FUNCTIONING
RECOMMENDATIONS FOR FUTURE INSTRUMENT DEVELOPMENT
SUMMARY
ACKNOWLEDGMENTS
55.3b Psychiatric Problems in the Medically Ill Geriatric Patient
APPROACH TO THE PATIENT
PSYCHIATRIC SYNDROMES IN MEDICALLY ILL PATIENTS
PSYCHIATRIC SYMPTOMS ASSOCIATED WITH SPECIFIC MEDICAL DISORDERS
SPECIAL ISSUES IN THE CARE OF OLDER ADULT PATIENTS
A HEALTH SYSTEMS APPROACH TO THE CARE OF THE MEDICALLY ILL GERIATRIC PATIENT
55.3c Sleep Disorders in Older Adults
SLEEP AND AGING
CONSEQUENCES OF POOR SLEEP IN OLDER ADULTS
SLEEP–WAKE DISORDERS IN OLDER ADULTS
INSOMNIA DISORDER
CIRCADIAN RHYTHM SLEEP–WAKE DISORDERS
OBSTRUCTIVE SLEEP APNEA–HYPOPNEA
RESTLESS LEGS SYNDROME/PERIODIC LIMB MOVEMENTS IN SLEEP
RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER
SLEEP IN NEUROCOGNITIVE DISORDERS
SLEEP IN NURSING HOMES
CONCLUSION
55.3d Anxiety Disorders in Older Adults
DEFINITION, HISTORY, AND COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY AND RISK FACTORS
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
FUTURE DIRECTIONS
55.3e Geriatric Mood Disorders
EPIDEMIOLOGY
SUBTYPES OF LATE-LIFE DEPRESSION
SUICIDE RISK
BIOLOGIC DYSFUNCTION
COURSE AND OUTCOME
EVALUATION AND TREATMENT OF GERIATRIC DEPRESSION AND BIPOLAR DISORDER
FUTURE DIRECTIONS
55.3f Alzheimer Disease and Other Neurocognitive Disorders
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
CLINICAL EVALUATION
IMAGING AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
TREATMENT
SUMMARY
55.3g Delirium
DEFINITION
HISTORY
COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
ETIOLOGY
DIAGNOSIS AND CLINICAL FEATURES
PATHOLOGY AND LABORATORY EXAMINATION
DIFFERENTIAL DIAGNOSIS
COURSE AND PROGNOSIS
PREVENTION
TREATMENT
FUTURE DIRECTIONS AND COVID CONSIDERATIONS
55.3h Schizophrenia and Other Psychotic Disorders
HISTORY AND COMPARATIVE NOSOLOGY
EPIDEMIOLOGY
EARLY-ONSET SCHIZOPHRENIA
LATE-ONSET SCHIZOPHRENIA
DIFFERENTIAL DIAGNOSIS OF PSYCHOTIC DISORDERS IN LATER LIFE
55.3i Personality Disorders
DEFINITIONS
EPIDEMIOLOGY
DIAGNOSIS
CLINICAL FEATURES AND COURSE
TREATMENT
55.3j Alcohol and Substance Abuse in Older Adults
HISTORY
DSM-5 TERMINOLOGY
ALCOHOL
TOBACCO
TETRAHYDROCANNABINOL
BENZODIAZEPINES
OPIOID ANALGESICS
ILLICIT DRUGS
NONPHARMACOLOGIC THERAPIES
FUTURE DIRECTIONS
55.4 Treatment of Psychiatric Disorders
55.4a Geriatric Psychopharmacology: General Principles
PHARMACOKINETIC CONSIDERATIONS
PHARMACODYNAMICS
FUTURE DIRECTIONS
ACKNOWLEDGMENT
55.4b Antidepressants and Mood Stabilizers
GOALS AND RATIONALE FOR THE PHARMACOLOGIC TREATMENT OF DEPRESSION IN LATER LIFE
PHARMACOLOGIC TREATMENT OF DEPRESSION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS
DUAL-ACTING ANTIDEPRESSANTS
BUPROPION
TRICYCLIC ANTIDEPRESSANTS
MONOAMINE OXIDASE INHIBITORS
STIMULANTS
TREATMENT OF PSYCHOTIC DEPRESSION IN LATER LIFE
TREATMENT OF DEPRESSION ASSOCIATED WITH MEDICAL ILLNESS AND COGNITIVE IMPAIRMENT
ESSENTIALS OF PATIENT MANAGEMENT
55.4c Antianxiety Drugs
ANTIDEPRESSANTS
BENZODIAZEPINES
BUSPIRONE
OTHER DRUGS
55.4d Antipsychotic Drugs
PHARMACOLOGIC ACTIONS
THERAPEUTIC INDICATIONS FOR ANTIPSYCHOTICS
TREATMENT PRINCIPLES
PRECAUTIONS AND ADVERSE REACTIONS
55.4e Antidementia Drugs
REGULATORY AND METHODOLOGIC CONSIDERATIONS
PHARMACOLOGIC TREATMENT OF SYMPTOMATIC BEHAVIORS OR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA
DRUGS TO TREAT DEMENTIA
INDIVIDUAL CHOLINESTERASE INHIBITORS: CLINICAL STUDIES, DOSING, AND ADVERSE EFFECTS
MEMANTINE: CLINICAL STUDIES, DOSING, AND ADVERSE EFFECTS
OTHER MEDICATIONS AND APPROACHES TO ALZHEIMER DISEASE AND COGNITIVE ENHANCEMENT
UNPROVEN AND UNSAFE MEDICATIONS TO SLOW CLINICAL PROGRESSION OR DELAY ONSET OF ALZHEIMER DISEASE
ADJUNCTIVE AND COMBINATION THERAPY
TREATMENT OF MILD COGNITIVE IMPAIRMENT
TREATMENT OF VASCULAR DEMENTIA
TREATMENT OF PARKINSON DISEASE DEMENTIA
β-Amyloid–Based Interventions
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
55.4f Electroconvulsive Therapy and Neurostimulation Treatments
BRIEF HISTORY AND BACKGROUND
PRECLINICAL STUDIES
CLINICAL INDICATIONS
PRE-ECT EVALUATION
NEUROCOGNITIVE ASSESSMENT
CONSENT
ECT PROCEDURES
ACUTE CLINICAL SAFETY AND EFFICACY
CONTINUATION AND MAINTENANCE ECT SAFETY AND EFFICACY
ECT ADVERSE EFFECTS
OTHER NEUROSTIMULATION THERAPIES
FUTURE DIRECTIONS
55.4g Psychosocial Factors in Psychotherapy of the Older Adults
RELATIONSHIPS
ROLE CHANGES
SOCIETAL ATTITUDES AND RESPONSES
ECONOMIC AND ENVIRONMENTAL FACTORS
ETHNOCULTURAL ISSUES
SPIRITUAL ISSUES
FUTURE DIRECTIONS
55.4h Individual Psychotherapy
HISTORY
THEORETICAL ISSUES
GENERAL TECHNIQUES
SUPPORTIVE PSYCHOTHERAPY
INTERPERSONAL PSYCHOTHERAPY
LIFE REVIEW OR REMINISCENCE THERAPY
COGNITIVE-BEHAVIORAL THERAPY
PROBLEM-SOLVING THERAPY
BRIEF (TIME-LIMITED) PSYCHODYNAMIC PSYCHOTHERAPY
INSIGHT-ORIENTED PSYCHOTHERAPY
MULTICOMPONENT PSYCHOTHERAPEUTIC INTERVENTIONS FOR FAMILY CGs
OTHER THERAPIES
CLINICAL ISSUES
ETHICAL ISSUES
FUTURE DIRECTIONS
55.4i Cognitive-Behavioral Therapy
DEFINITION
ADAPTING CBT FOR OLDER CLIENTS
TECHNIQUES
CLINICAL ISSUES
RESEARCH AND EVALUATION
55.4j Family Intervention and Therapy with Older Adults
HISTORY
THEORETICAL ISSUES
TECHNIQUES
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
55.4k Group Therapy
HISTORY
THEORETICAL ISSUES
TECHNICAL INTERVENTIONS AND GROUP APPROACHES
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
FUTURE DIRECTIONS
55.4l Counseling and Support Needs of Dementia Caregivers
INTRODUCTION AND DEFINITION OF CAREGIVING
HISTORY AND THEORETICAL ISSUES
TECHNIQUES FOR PREVENTING AND MANAGING CAREGIVER DISTRESS
CLINICAL ISSUES
ETHICAL ISSUES
RESEARCH AND EVALUATION
55.5 Financial Issues in the Delivery of Geriatric Psychiatric Care
DEMOGRAPHIC TRENDS AND THE COST OF HEALTH CARE FOR OLDER ADULTS
HISTORICAL BACKGROUND
MEDICARE SYSTEM
MEDICAID SYSTEM
OUT-OF-POCKET COSTS
PATIENT PROTECTION AND AFFORDABLE CARE ACT AND MENTAL HEALTH PARITY
ACCOUNTABLE CARE ORGANIZATIONS AND VALUE-BASED OUTCOMES
CURRENT AND FUTURE DIRECTIONS
55.6 Special Areas of Interest
55.6a Psychiatric Aspects of Long-Term Care
APPROACH TO EVALUATING AND MANAGING PSYCHIATRIC SYMPTOMS AND DISORDERS
DELIRIUM AND PSYCHIATRIC ASPECTS OF COMORBID MEDICAL CONDITIONS
SPECIFIC DISORDERS AND LONG-TERM CARE
PSYCHIATRIC ASPECTS OF PALLIATIVE CARE
55.6b Forensic Aspects
CRIMINAL ASPECTS OF FORENSIC GEROPSYCHIATRY
CIVIL ASPECTS OF FORENSIC GEROPSYCHIATRY
GENERAL CONCEPTS IN CIVIL FORENSIC GEROPSYCHIATRY
ADMINISTRATIVE ASPECTS OF FORENSIC GEROPSYCHIATRY
CORRECTIONAL ASPECTS OF FORENSIC GEROPSYCHIATRY
NOSOLOGIC/THEORETICAL ISSUES
55.6c Ethical Issues
THE FOCUSING EFFECT OF A FRAMEWORK
GENERAL APPLICATIONS OF THE CORE PRINCIPLES TO GERIATRIC MENTAL HEALTH CARE
OPERATIONALIZING RESPECT FOR AUTONOMY: DECISION-MAKING CAPACITY AND THE DOCTRINE OF INFORMED CONSENT
55.6d Gender Issues
IMPACT OF GENDER ON PSYCHIATRIC CONDITIONS
TREATMENT ISSUES
FUTURE DIRECTIONS
ACKNOWLEDGMENTS
55.6e The Legal and Ethical Analysis of Older Adult Abuse
DEFINITIONS
NOSOLOGY
FACTORS ASSOCIATED WITH OLDER ADULT VULNERABILITY
MULTIDISCIPLINARY TEAMS
THE RED FLAGS AND INDICATORS OF OLDER ADULT ABUSE
SENIORS AND THE COURT SYSTEM
ESTABLISHING A “THEFT” IN OLDER ADULT FINANCIAL ABUSE
EXCUSES AND JUSTIFICATIONS IN OLDER ADULT ABUSE
ETHICAL ANALYSIS OF SUSPECTED OLDER ADULT ABUSE
CORONAVIRUS 19 (COVID-19) AND OLDER ADULT ABUSE
CONCLUSION
CASES
55.6f Geriatric Psychiatry: Sexuality and Aging
NEUROBIOLOGY OF SEXUAL FUNCTION
AGE-RELATED CHANGES IN SEXUAL FUNCTION AND BEHAVIOR
GENDER AND SEXUAL MINORITIES IN LATER LIFE
HOW TO OBTAIN A SEXUAL HISTORY
HOW TO ASSESS SEXUAL DYSFUNCTIONS IN OLDER PATIENTS
THE TREATMENT OF SEXUAL DYSFUNCTION IN OLDER ADULTS
SEXUAL BEHAVIOR IN LONG-TERM CARE
CASE EXAMPLE
55.6g HIV and Aging
EPIDEMIOLOGY
PREVENTION
NEUROCOGNITIVE OUTCOMES OF HIV AND AGING
MENTAL HEALTH OUTCOMES OF HIV AND AGING
COMORBIDITY AND MULTIMORBIDITY
IMPACT ON EVERYDAY FUNCTIONING
THE SPECIAL CASE OF THE VETERAN POPULATION
TREATMENT AND MANAGEMENT
FUTURE DIRECTIONS
55.6h Technology for Seniors
COMPARATIVE NOSOLOGY
SPECIFIC APPLICATIONS OF TECHNOLOGY
FUTURE DIRECTIONS
BARRIERS AND LIMITATIONS
55.6i Positive Psychiatry of Aging
DEFINING POSITIVE PSYCHIATRY
HISTORY
POSITIVE MENTAL HEALTH OUTCOMES
POSITIVE PSYCHOSOCIAL FACTORS
POSITIVE PSYCHOSOCIAL CHARACTERISTICS
BIOLOGY OF POSITIVE PSYCHIATRY
INTERVENTIONS
56 Public Psychiatry
56.1 Public and Community Psychiatry
WHAT IS COMMUNITY PSYCHIATRY?
THE ROOTS OF COMMUNITY PSYCHIATRY
ORGANIZED SYSTEMS OF CARE
THE RECIPIENTS OF COMMUNITY PSYCHIATRIC CARE
THE ROLE OF THE PSYCHIATRIST IN COMMUNITY PSYCHIATRY
THE INPATIENT TO OUTPATIENT AND COMMUNITY PSYCHIATRY CONTINUUM
STIGMA AND DISCRIMINATION–AN OPPORTUNITY FOR COMMUNITY PSYCHIATRY
COMMUNITY PSYCHIATRY AND THE PUBLIC SECTOR
BARRIERS TO ACCESS
COMMUNITY PSYCHIATRY AND RECOVERY
ATTITUDES TOWARD COMMUNITY PSYCHIATRY
COMMUNITY PSYCHIATRY AND PSYCHIATRIC TRAINING
TELEPSYCHIATRY IN THE COMMUNITY
ASSETS AND ADVANTAGES OF ONGOING PROGRAMS
THE LARGER PICTURE
56.2 Reforming Health Care
HEALTH CARE REFORM IN THE 20TH CENTURY: A HISTORICAL OVERVIEW
HEALTH CARE REFORM IN THE 21ST CENTURY
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) AND THE TRIPLE AIM DEFINITION—APPLICATIONS TO MENTAL HEALTH
IMPROVING MODELS IN HEALTH CARE: THE ACA A DECADE LATER
HEALTH INFORMATION TECHNOLOGY (HIT) AND ELECTRONIC HEALTH RECORDS (EHR)
56.3 The Role of the Hospital in the Care of Persons with Mental Illness
THE HISTORICAL EVOLUTION OF THE ROLE OF THE HOSPITAL
DEFINING THE ROLE OF THE PSYCHIATRIC HOSPITAL
FULFILLING THE ROLE
SPECIAL POPULATIONS
OTHER HOSPITAL ROLES
FUTURE DIRECTIONS
56.4 Mental Health Services Research
THE SCOPE OF MENTAL HEALTH SERVICES RESEARCH
OVERVIEW
56.5 The Psychiatric Hospitalist
THE DEFINITION OF HOSPITALIST PHYSICIANS
ROLES OF THE HOSPITALIST
THE PSYCHIATRIC HOSPITALIST
HISTORY OF THE MODERN HOSPITALIST MOVEMENT
THE STAGES OF HOSPITAL CARE
BENEFITS FROM THE USE OF HOSPITALISTS
HOSPITALISTS AS CLINICIAN-EDUCATORS
DISADVANTAGES AND OBJECTIONS TO THE HOSPITALIST MODEL
PROFESSIONAL ORGANIZATIONS
SPECIALTY TRAINING AS A HOSPITALIST
FINANCIAL, POLITICAL, AND ORGANIZATIONAL ISSUES
HOSPITAL MEDICINE AS A NEW SPECIALTY
FUTURE DIRECTIONS
56.6 Psychiatric Rehabilitation
PSYCHIATRIC REHABILITATION IN THE MEDICAL SETTING
UNIFYING CONCEPTS OF PSYCHIATRIC REHABILITATION AND TREATMENT
PSYCHIATRIC REHABILITATION AND INCORPORATION OF PERSON-CENTERED RECOVERY MODELS
DEFINING RECOVERY
EMPIRICALLY BASED MODELS OF PSYCHIATRIC REHABILITATION
ACCESSIBILITY TO EVIDENCE-BASED TREATMENT AND SERVICES
REHABILITATION IN THE PRODROMAL, ACUTE, AND STABLE PHASES OF SEVERE MENTAL ILLNESS
ASSESSMENT IN PSYCHIATRIC REHABILITATION
SPECIFIC APPROACHES
COMORBID SUBSTANCE USE DISORDERS
TOWARD MORE INTEGRATIVE MODELS OF CARE
56.7 A Sociocultural Framework for Mental Health and Substance Abuse Service Inequities
THE SOCIOCULTURAL FRAMEWORK: A COMPLEX, POPULATION HEALTH SYSTEMS APPROACH
HEALTH CARE SYSTEM DOMAINS
THE COMMUNITY SYSTEM
WHEN HEALTH CARE SYSTEMS AND COMMUNITY SYSTEMS MEET: MECHANISMS PRODUCING INEQUITIES
FUTURE DIRECTIONS: RESEARCH AND INTERVENTION
ACKNOWLEDGMENTS
56.8 Criminalization of Persons With Serious Mental Illness
MAGNITUDE OF THE PROBLEM
DEFINING CRIMINALIZATION
CAUSES OF CRIMINALIZATION
MENTAL ILLNESS AND VIOLENCE
SOME CHARACTERISTICS OF PERSONS WITH SERIOUS MENTAL ILLNESS WHO ARE INCARCERATED
MENTAL HEALTH SERVICES AFTER ARREST
OUTPATIENT TREATMENT TO REVERSE OR PREVENT CRIMINALIZATION
57 Psychiatric Education
57.1 Graduate Psychiatric Education
HISTORY OF PSYCHIATRIC EDUCATION
PSYCHIATRIC EDUCATION TODAY
RELATION TO CHANGES IN MEDICAL EDUCATION
57.2 Examining Professional Patients
PSYCHIATRIC RESIDENCY AS A MODEL OF PROFESSIONAL LEARNING, GROWTH, AND MATURATION
PROFESSIONAL CRISES IN LATER YEARS
TREATMENT: UNFOLDING INTO THE SYSTEM, REPEATING THE STORIES OF THEIR LIVES
58 Ethics and Forensic Psychiatry
58.1 Clinical-Legal Issues in Psychiatry
THE DOCTOR–PATIENT RELATIONSHIP
MEDICAL DECISION-MAKING AND COMPETENCE
INVOLUNTARY HOSPITALIZATION AND TREATMENT
CONFIDENTIALITY AND PRIVILEGE
PSYCHIATRIC MALPRACTICE
THE PSYCHIATRIST AS AN EXPERT
CHILDREN AND THE LAW
58.2 Ethics in Psychiatry
ETHICAL SCHOOLS OF THOUGHT
BASIC ETHICAL PRINCIPLES
APPROACHING ETHICAL DILEMMAS
DECISION-MAKING STRATEGIES
EXAMPLES OF ETHICAL PRACTICE STANDARDS IN PSYCHIATRY
ETHICS AS FUNDAMENTAL TO MEDICAL PROFESSIONALISM
58.3 Correctional Psychiatry
PSYCHIATRIC PATIENTS IN CORRECTIONAL FACILITIES
HISTORY OF CORRECTIONAL PSYCHIATRY IN THE UNITED STATES
PERSISTING CHALLENGES IN CORRECTIONAL PSYCHIATRY
THE LEGAL AND ETHICAL PRINCIPLES UNDERLYING THE PRACTICE OF CORRECTIONAL PSYCHIATRY
PSYCHIATRIC TREATMENT IN JAILS AND PRISONS
THE FUTURE OF CORRECTIONAL PSYCHIATRY
ACKNOWLEDGMENT
59 History of Psychiatry
EARLY BEGINNINGS
THE FIRST BIOLOGIC PSYCHIATRY
PSYCHOTHERAPY, SOCIAL PSYCHIATRY
FROM ASYLUM TO UNIVERSITY
DIAGNOSIS
NEW TECHNIQUES
THE BEGINNING OF THE SECOND BIOLOGIC PSYCHIATRY
PEDIATRIC PSYCHIATRY
NEW FORMS OF CARE
60 World Aspects of Psychiatry
PREVALENCE AND BURDEN OF MENTAL DISORDERS WORLDWIDE
TREATMENT GAP AND PROJECTED POPULATION-LEVEL TREATMENT EFFECTIVENESS WORLDWIDE
RESOURCES FOR MENTAL HEALTH CARE WORLDWIDE
PRINCIPLES FOR MENTAL HEALTH PROGRAM DEVELOPMENT WORLDWIDE
BARRIERS TO CHANGE
STIGMATIZING ATTITUDES TOWARD PEOPLE WITH MENTAL DISORDERS
RELATIONSHIPS BETWEEN MENTAL AND PHYSICAL DISEASES
ETHICAL ISSUES IN MENTAL HEALTH CARE
INTERNATIONAL ORGANIZATIONS ACTIVE IN THE MENTAL HEALTH FIELD
FUTURE PERSPECTIVES
FUTURE DIRECTIONS
Appendix A : History of Psychiatry Table
Appendix B : Glossary of Psychiatry and Psychology Terms
Appendix C : Comparative Diagnoses
Index
An aparitie | 8 mai 2024 |
Autor | Robert Boland, Marcia Verduin |
Dimensiuni | 213 x 276 mm |
Editura | LWW |
Format | Hardcover |
ISBN | 9781975175733 |
Limba | Engleza |
Nr pag | 5500 |
Clientii ebookshop.ro nu au adaugat inca opinii pentru acest produs. Fii primul care adauga o parere, folosind formularul de mai jos.